triazoles has been researched along with nefazodone in 460 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.43) | 18.7374 |
| 1990's | 205 (44.57) | 18.2507 |
| 2000's | 218 (47.39) | 29.6817 |
| 2010's | 30 (6.52) | 24.3611 |
| 2020's | 5 (1.09) | 2.80 |
| Authors | Studies |
|---|---|
| Eison, MS; Pasternak, GW; Paul, D; Pick, CG | 1 |
| Fontaine, R | 2 |
| Cowen, PJ; Sharpley, AL; Walsh, AE | 1 |
| Balster, RL; Gold, LH | 1 |
| Duncan, GF; Farmen, RH; Franc, JE; Pittman, KA | 1 |
| Copp, JE; Robinson, DS; Schwiderski, UE | 1 |
| Copp, J; D'Amico, MF; Roberts, DL; Robinson, DS; Schwiderski, UE | 1 |
| Eison, AS; Eison, MS; Torrente, JR; Wright, RN; Yocca, FD | 1 |
| Boyer, WF; D'Amico, MF; Feighner, JP; Fowler, RC; Pambakian, R | 1 |
| Crews, FT; Scott, JA | 1 |
| Ieni, JR; Knight, DL; Nemeroff, CB; Owens, MJ; Winders, K | 1 |
| Anton, SF; Revicki, DA | 1 |
| Goldberg, RJ | 3 |
| Kupecz, D | 1 |
| Sussman, N | 1 |
| Chaikin, PC; Dockens, RC; Fulmor, IE; Milbrath, RL; Raymond, RH; Salazar, DE; Uderman, HD | 1 |
| Barbhaiya, RH; Behr, DA; Greene, DS; Natarajan, CS; Sainati, SM; Shukla, UA | 1 |
| al-Jeshi, A; Jeffries, JJ | 1 |
| Nelson, EC | 1 |
| Preskorn, SH | 2 |
| Carter, RB; Eison, AS; Mullins, UL; Smith, HL; Taylor, DP; Torrente, JR; Wright, RN; Yocca, FD | 1 |
| Anton, SF; Francis, RJ; Marcus, RN; Mendels, J; Reimherr, F; Roberts, DL | 1 |
| Anton, SF; Fawcett, J; Marcus, RN; O'Brien, K; Schwiderski, U | 1 |
| Marcus, RN; Rickels, K; Roberts, DL; Robinson, DS; Schweizer, E | 1 |
| van Laar, MW; van Willigenburg, AP; Volkerts, ER | 1 |
| McBrayer, RH; Rose, FV; Ware, JC | 1 |
| Nemeroff, CB | 1 |
| Anton, SF; Archibald, DG; English, PA; Kensler, TT; Roberts, DL; Robinson, DS | 1 |
| Ansseau, M; Darimont, P; De Nayer, A; Devoitille, JM; Dierick, M; Evrard, JL; Krémer, P; Lecoq, A; Mertens, C; Mesotten, F | 1 |
| Bernard, N; Cuisinaud, G; Ferry, N; Rougier, P; Sassard, J; Trepo, C | 1 |
| Clary, C; Fox, I; Rickels, K; Schweizer, E; Weise, C | 1 |
| Cowen, PJ; Walsh, AE | 1 |
| Armitage, R; Cain, J; Roffwarg, HP; Rush, AJ; Trivedi, M | 1 |
| Denis, A; Freeman, EW; Pfeifer, S; Rickels, K; Sondheimer, SJ; Weil, S | 1 |
| Fuller, RW; Hemrick-Luecke, SK; Snoddy, HD | 1 |
| Ecker, JA; Elie, R; Faludi, G; Fontaine, R; Kaplita, S; Kensler, TT; Ontiveros, A; Roberts, DL | 1 |
| Campling, G; Cowen, PJ; Hockney, RA; Walsh, AE | 1 |
| Frewer, LJ; Lader, M | 1 |
| Barbhaiya, RH; Kaul, S; Shukla, UA | 1 |
| Cloninger, CR; Nelson, EC | 1 |
| Barbhaiya, RH; Greene, DS; Shukla, UA | 2 |
| Barbhaiya, RH; Gammans, RR; Greene, DS; Marathe, PH; Mayol, RF; Pittman, KA; Robinson, D; Shukla, UA | 1 |
| Barbhaiya, RH; Brennan, J; Greene, DS; Marathe, PH; Salazar, DE; Shukla, UA | 1 |
| Debattista, C; Sofuoglu, M | 1 |
| Pollack, MH; Worthington, JJ | 1 |
| Ashton, AK; Wolin, RE | 1 |
| Zajecka, JM | 1 |
| Cohn, CK; Ieni, JR; O'Brien, K; Roberts, DL; Robinson, DS; Schwiderski, UE | 1 |
| Marcus, RN; Mendels, J | 1 |
| Montgomery, SA | 1 |
| Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC | 1 |
| Lader, MH | 1 |
| Abed, RT; Ascher, A; Baldwin, DS; Buckingham, SA; Cox, J; Hawley, CJ; Maragakis, BP; Pover, GH | 1 |
| Feiger, A; Kiev, A; Shrivastava, RK; Wilcox, CS; Wisselink, PG | 1 |
| Archibald, DG; Hardy, SA; Marcus, RN; Robinson, DS | 1 |
| Fulmor, IE; Lee, JS; Marathe, PH; Raymond, RH; Salazar, DE; Uderman, HD | 1 |
| Rothschild, AJ | 1 |
| Barbhaiya, RH; Brady, ME; Greene, DS; Shukla, UA | 1 |
| DeMartinis, NA; Rickels, K; Schweizer, E | 1 |
| Callahan, AM; Ketter, TA; Post, R | 1 |
| Shammi, C | 1 |
| Ghaemi, SN; Irizarry, MC | 1 |
| Curtis, SL; Hatton, RC; Helms-Smith, KM | 1 |
| Barbhaiya, RH; Dockens, RC; Greene, DS; Rapoport, D; Roberts, D | 1 |
| Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Barbhaiya, RH; Chaikin, P; Greene, DS; Marathe, PH; Shukla, UA | 1 |
| Barbhaiya, RH; Dockens, RC; Greene, DS; Kroboth, P; Salazar, DE | 2 |
| Ellingrod, VL; Perry, PJ | 1 |
| Brown, RE; Clark, M; Montgomery, SA | 1 |
| Barbhaiya, RH; Greene, DS; Lee, JS; Marathe, PH | 1 |
| Barbhaiya, RH; Dandekar, KA; Greene, DS | 1 |
| Barbhaiya, R; Chaikin, PC; Folan, MM; Kroboth, PD; Lush, RM; Salazar, DE; Shukla, UA | 1 |
| Barbhaiya, RH; Greene, DS; Kroboth, PD; Shukla, UA | 1 |
| Kraus, RP | 1 |
| Barbhaiya, RH; Buch, AB; Greene, DS | 2 |
| Barbhaiya, RH; Breul, HP; Greene, DS; Midha, KK; Shukla, UA | 1 |
| Barbhaiya, RH; Dockens, RC; Greene, DS | 2 |
| Attenburrow, ME; Cowen, PJ; Pearson, G; Sargent, P; Sharpley, AL; Williamson, DJ | 1 |
| Stoudemire, A | 1 |
| Brown, CS; Cyr, M | 1 |
| Bryant, SG | 1 |
| Adler, LA; Angrist, B; Eberstein, S | 1 |
| Simpson, JS | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Micheal, A; Ramana, R | 1 |
| Langer, SF; Pecknold, JC | 1 |
| Duan, SX; Fogelman, SM; Greenblatt, DJ; Harmatz, JS; Kudchadker, L; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Blaisdell, GD; Jermain, DM; Zaphiris, HA | 1 |
| Halls, CH; Hedges, DW; Reimherr, FW; Rust, C; Strong, RE | 1 |
| Hammett, JL; Langenbacher, KM; Marino, MR; Nichola, P; Uderman, HD | 1 |
| Puzantian, T; Shaw, RJ | 1 |
| Gilroy, WR; Gupta, S | 1 |
| Biggs, F; Warnock, JK | 1 |
| Blew, PG; John, L; Perreault, MM; Tao, T | 1 |
| Clark, A; Livingston, MG | 1 |
| Brown, RE; Culpepper, L; Gonzales, J; Hales, RE; Keller, MB; Revicki, DA | 1 |
| Reynolds, RD | 1 |
| Dubin, H; Giannandrea, P; Spier, S | 1 |
| Bryson, HM; Davis, R; Whittington, R | 1 |
| Biederman, J; Schleifer, D; Spencer, TJ; Wilens, TE | 1 |
| Möller, HJ; Volz, HP | 1 |
| Yonkers, KA | 1 |
| Armitage, R; Cole, D; Rush, AJ; Yonkers, K | 1 |
| Fogelson, DL | 1 |
| Albala, BJ; Erman, MK; Gillin, JC; Rapaport, M; Winokur, A | 1 |
| Benazzi, F | 3 |
| Schwartz, K | 1 |
| van Laar, MW | 1 |
| Bakish, D; Hooper, CL; Miller, CA; Thibaudeau, CA; Thornton, MD; Wiens, A | 1 |
| Frazer, A | 1 |
| Nelson, JC | 1 |
| Cloninger, CR; Nelson, E | 1 |
| Cowen, PJ; Odontiadis, J; Pearson, G; Sargent, P; Williamson, DJ | 1 |
| Blanc, PD; Brazelton, T; Olson, KR | 1 |
| Peak, DA | 1 |
| Barbhaiya, RH; Greene, DS | 1 |
| Morgan, WN; Nemeroff, CB; Owens, MJ; Plott, SJ | 1 |
| Engel, JA; Ericson, M; Kosowski, A; Olausson, P; Petersson, A; Söderpalm, B | 1 |
| Sayegh, MH; Vella, JP | 1 |
| Anderson, G; Cellar, J; Mallison, RT; Narayan, M; Nelson, JC; Price, LH | 1 |
| Cohen, J; Kaplita, S; Kensler, T; Mullis, D; Vogal, G | 1 |
| Stahl, SM | 3 |
| Yong, JN | 1 |
| Brotto, LA; Gorzalka, BB; Hanson, LA | 2 |
| Segraves, RT | 1 |
| Case, WG; DeMartinis, N; Garcia España, FG; Greenblatt, DJ; Mandos, LA; Rickels, K; Schweizer, E | 1 |
| Nemeroff, CB; Owen, JR | 1 |
| Bennett, ME; D'Amico, MF; Feighner, J; Hardy, SA; Kensler, TT; Roberts, DL; Targum, SD | 1 |
| Berigan, TR; Casas, A; Harazin, J | 1 |
| Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA | 1 |
| Connor, KM; Davidson, JR; Malik, ML; Weisler, RH | 1 |
| Richelson, E | 1 |
| Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Moore, SD | 2 |
| Hamilton, SP; Klimchak, C; Nunes, EV | 1 |
| Campo, JV; Perel, JM; Smith, C | 1 |
| Beeson, MS; Gaffney, PN; Schuckman, HA | 1 |
| Shah, VR; Shyu, WC; Srinivas, NR; Yao, M | 1 |
| Fones, CS; Otto, MW; Pollack, MH; Worthington, JJ; Zucker, BG | 1 |
| McBrayer, RH; Ware, JC | 1 |
| Caccia, S; Cervo, L; Fracasso, C; Guiso, G; Nacca, A | 1 |
| Balon, R | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Aranda-Michel, J; Balistreri, WF; Bejarano, PA; Ee, LC; Khan, CM; Koehler, A; Luxon, BA; Poulos, JE; Weber, FL | 1 |
| Mancini, C; Oakman, JM; Van Ameringen, M | 1 |
| Greenberg, WM | 1 |
| Anton, SF; Bakish, D; Brown, RE; Feeny, D; Palmer, W; Revicki, DA; Rosser, WW | 1 |
| Benfield, P; Wilde, MI | 1 |
| Cheuvart, B; Cosson, JP; Decourt, JP; Girault, J; Ingrand, I; Istin, B; Laroudie, C; Salazar, DE | 2 |
| Chen, S; Churchill, E; Davidson, J; Hertzberg, MA; Hidalgo, R; Mellman, T; Petty, F; Tucker, P; Weisler, R; Zisook, S | 1 |
| Bergam, K; Claypoole, K; Elliott, AJ; Roy-Byrne, PP; Russo, J; Uldall, KK | 1 |
| Archibald, DG; Bielski, RJ; Bremner, J; Feiger, AD; Heiser, JF; Kaplita, SB; Kensler, TT; McQuade, RD; Roberts, DL; Trivedi, M; Wilcox, CS | 1 |
| Lauber, C | 1 |
| Markowitz, JS | 1 |
| Goodnick, PJ; Jorge, CM | 1 |
| Horst, WD; Preskorn, SH | 1 |
| Hickie, I | 1 |
| Roberts-Thompson, IC; Schrader, GD | 1 |
| Barza, L; David, D; Mellman, TA | 1 |
| Belton, J; DeVega, E; DiGiovanni, S; Fuller, M; Liebling, D; Marqua, S; Sajatovic, M | 1 |
| Brewer, ER; Carson, SW; Golding, M; Kotlyar, M | 2 |
| Berkowitz, DV; Conrad, C; McDannold, M; Scharf, MB; Spinner, O; Stover, R; Zaretsky, N | 1 |
| Cho, R; Kapur, S; Kennedy, S; Meyer, JH | 1 |
| Bodani, M; Hubbeling, A; Murray, R; Taylor, D | 1 |
| Granda, BW; Grassi, JM; Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Thase, ME | 1 |
| Hirschfeld, RM | 1 |
| Buist, A; Burrows, GD; Dodd, S; Maguire, KP; Norman, TR | 1 |
| Appelberg, B; Joffe, G; Rimón, R | 1 |
| Brodie-Meijer, CC; Buijs, PJ; Diemont, WL | 1 |
| Little, J; Rajagopalan, M | 1 |
| El-Mallakh, RS | 1 |
| Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M | 1 |
| Shuster, J | 1 |
| Burda, A; Chan, SB; Leikin, JB; Stokes, KA; Webster, K | 1 |
| DeVane, CL; Pollock, BG | 1 |
| Bruhn, PS; Emery, RW; Lake, KD; Wright, DH | 1 |
| al-Dubai, Z; Beraus, W; Conca, A; König, P | 1 |
| Horton, JC; Trobe, JD | 1 |
| Hollander, Y; Leung, M; Mosberian, P; Remick, RA | 1 |
| Pies, R | 1 |
| Bystritsky, A; Rosen, R; Suri, R; Vapnik, T | 1 |
| Andrade, RJ; Cabello, MR; Gomez-Outes, A; Lucena, MI; Rubio, M | 1 |
| Churchill, E; Davidson, JR; Meltzer-Brody, S | 1 |
| Srinivas, NR; Yao, M | 1 |
| Fava, M | 1 |
| Kranzler, HR; Modesto-Lowe, V; Van Kirk, J | 1 |
| Smith, DL; Wenegrat, BG | 1 |
| Kent, JM | 1 |
| Davidson, JR | 1 |
| Blume, AW; Cowley, DS; Jaffe, C; Kingsley, E; Pages, KP; Ries, RK; Roy-Byrne, PP; Russo, JE | 1 |
| Davis, LL; Kramer, GL; Murray, J; Nugent, AL; Petty, F | 1 |
| Benzick, JM; Faber, RA | 1 |
| Bottorf, MB | 1 |
| Michael, A; Praseedom, A; Tubbe, PA | 1 |
| Eloubeidi, MA; Gaede, JT; Swaim, MW | 1 |
| Arnow, B; Dunner, DL; Gelenberg, AJ; Keller, MB; Klein, DN; Markowitz, JC; McCullough, JP; Nemeroff, CB; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J | 1 |
| Scott, J | 1 |
| Chentsova-Dutton, YE; Ellenor, GL; Gillin, JC; Kline, NA; Kodsi, AB; Smith-Vaniz, A; Zisook, S | 1 |
| Lerner, V; Matar, MA; Polyakova, I | 1 |
| Dunn, NR; Mackay, FJ; Mann, RD | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Coleman, E; Gratzer, T; Nesvacil, L; Raymond, NC | 1 |
| Chouinard, G; Margolese, HC | 1 |
| Balboa, J; Freire-Garabal, M; Liñares, D; Mañá, P; Mayán, JM; Núñez, MJ; Rey-Méndez, M; Riveiro, P; Varela, M | 1 |
| Baretton, G; Schirren, CA | 1 |
| Jurima-Romet, M; Neigh, S; Wright, M | 1 |
| Goodnick, PJ; Hunter, T; Jorge, CA; Kumar, AM | 1 |
| Breakstone, K; Goodnick, PJ; Kumar, A; Wen, XL | 1 |
| Kocsis, JH | 1 |
| Andersen, MS; Domon, SE | 1 |
| D'Amico, F; Findling, RL; Magnus, RD; Marathe, P; Marcus, RN; Preskorn, SH; Reed, MD | 1 |
| Baty, P | 1 |
| D'Mello, DA; Meland, R; Ransom, S | 1 |
| Khouzam, HR | 2 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Benson, BE; Butler, AY; Dahl, B; Easom, LA; Foley, MM; Mathiason, M; Smith, K | 1 |
| Coplan, JD; de Jesus, M; Gorman, JM; Martinez, JM; Papp, LA | 1 |
| Rubin, RT | 1 |
| Umanoff, DF | 1 |
| Duncan, BL; Miller, SD | 1 |
| Veijola, JM | 1 |
| de Man, RA; Metselaar, HJ; van Battum, PL; van de Vrie, W; Verstappen, VM; Zondervan, PE | 1 |
| Carney, SL; Colvin, EM; Lucaites, VL; Nelson, DL; Pullar, IA; Wedley, S | 1 |
| Hartmann, E; Koenig, E; Müller, F; Scheidtmann, K | 1 |
| Hackett, LP; Ilett, KF; Kristensen, JH; Paech, MJ; Rampono, J; Yapp, P | 1 |
| Burrows, GD; Dodd, S; Maguire, KP; Norman, TR | 1 |
| MacDonald, J; Rawlins, S | 1 |
| Agelink, MW; Klieser, E; Linka, T; Majewski, T; Postert, T; Rotterdam, S; Wurthmann, C | 1 |
| Izquierdo, JA; Llorca, G; Montejo, AL; Rico-Villademoros, F | 1 |
| Ferguson, JM | 1 |
| Baker, SM; Trivedi, MH | 1 |
| Borian, F; Ferguson, JM; Hartford, JT; Ieni, J; Jody, D; McQuade, RD; Shrivastava, RK; Stahl, SM | 1 |
| Abernethy, DR; Barbey, JT; Brown, KS; Feirrera, I; Ford, N; Franc, J; Salazar, DE | 1 |
| Chen, L; Srinivas, NR; Yao, M | 1 |
| Finkel, B; Katz, S; Kodesh, A; Lerner, AG; Sigal, M | 1 |
| Carmody, TJ; Pan, JY; Rush, AJ; Trivedi, MH | 1 |
| Dunner, DL | 1 |
| Bikoff, J; Ginsberg, DL; Sussman, N | 1 |
| Lake, AE; Saper, JR; Tepper, SJ | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Blanco, C; Davies, S; Goetz, D; Lewis-Fernández, R; Liebowitz, M; Salmán, E; Sánchez-Lacay, JA | 1 |
| Huang, M; Jemal, M; Mao, Y; Powell, ML; Whigan, D | 1 |
| Khan, AY; Preskorn, SH | 1 |
| Andersch, B; Eriksson, E; Eriksson, O; Landén, M; Naessén, T; Sundblad, C | 1 |
| Volz, HP | 1 |
| Devarajan, S; Dursun, SM; Kutcher, S | 1 |
| Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL | 1 |
| Baruch, Y; Chelben, J; Lustig, M; Strous, RD | 1 |
| Graeff, FG; Guimarães, FS; Hetem, LA; Silva, M | 1 |
| Bertschy, G; Roth, L | 1 |
| Geetha, S; Om Reddy, G; Sreenivas Rao, D; Srinivasu, MK | 1 |
| Jerome, L | 1 |
| Fichtner, CG; Garfield, DA; Leveroni, C; Mahableshwarkar, A | 1 |
| Baldwin, DS; Hawley, CJ; Mellors, K | 1 |
| Keller, MB | 1 |
| Alderman, CP; Condon, JT; Gebauer, MG; Gilbert, AL | 1 |
| Chu, J; Henderson, W; Hoffman, R | 1 |
| Adson, DE; Kotlyar, M | 1 |
| Allen, L; Escobar, J; Hamer, RM; Lauritano, M; Menza, M; Ostella, F; Warman, M | 1 |
| Ehrenthal, HD; Ströhle, A | 1 |
| Brown, GR; Chinouth, R; Coyle, BR; Miller, BE; Miller, MN | 1 |
| Gillin, JC; Goyette, LM; Kelsoe, J; Marler, MR; Raimo, E; Rapaport, MH; Schnierow, B; Smith-Vaniz, A; Stein, MB; Zisook, S | 1 |
| Borian, FE; Crits-Christoph, P; Dunner, DL; Hirschfeld, RM; Keitner, G; Keller, MB; Klein, DN; Koran, LM; Kornstein, SG; Markowitz, JC; Miller, I; Nemeroff, CB; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH | 1 |
| Baker, GB; Rotzinger, S | 1 |
| Carvajal García-Pando, A; García del Pozo, J; Lucena, MI; Rueda de Castro, AM; Sánchez, AS; Velasco, MA | 1 |
| Schwetz, BA | 1 |
| DeVane, CL; Grothe, DR; Smith, SL | 1 |
| Keller, MB; Laird, LK; Prather, MR; Rush, AJ; Schatzberg, AF; Wright, CW | 1 |
| Brady, KT; Charney, DS; Grothe, DR; Kaltsounis-Puckett, J; Laird, LK; Rush, AJ; Smith, SL; Wright, CW | 1 |
| Bailey, L; Dunner, DL; Laird, LK; Seabolt, JL; Sussman, N; Zajecka, J | 1 |
| Lusk, KM; McEnany, GW; Zajecka, J | 1 |
| Brunson, GH; Hales, RE; Hilty, DM | 1 |
| Barbey, JT | 1 |
| Stewart, DE | 1 |
| Borian, FE; Crits-Christoph, P; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J | 1 |
| Argyropoulos, SV; Bell, CJ; Edwards, C; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Borian, FE; Dunner, DL; Friedman, ES; Keller, MB; Klein, DN; Kornstein, SG; Manber, R; Markowitz, JC; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH | 1 |
| Balboa, J; Freire-Garabal, M; Núñez, LA; Núñez, MJ; Rey-Méndez, M; Rivas, M; Riveiro, P; Suárez, J | 1 |
| Arias, F; Carrasco, JL; Díaz-Marsá, M; Huertas, D; Ibañez, A; Martín-Carrasco, M; Moreno, I; Rico-Villademoros, F; Saiz-Ruiz, J | 1 |
| Kenemans, JL; Trooster, S; van Laar, MW; van Megen, HJ; Verbaten, MN; Volkerts, ER | 1 |
| Bird, D; Dursun, SM; Ronson, KE | 1 |
| Arnow, BA; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J | 1 |
| Samuels, S; Thompson, M | 1 |
| Ehrentraut, S; Gerbes, AL; Kapfhammer, HP; Rau, HG; Rothenhäusler, HB; Schirren, CA; Thiel, M | 1 |
| Garton, T | 1 |
| Maddens, ME; Toofanny, N | 1 |
| Abecia, LC; Casado, A; Casis, L; Echevarría, E; Macarulla, MT; Portillo, MP; Rodríguez, VM; Saracíbar, G | 1 |
| Ninan, PT | 1 |
| Haney, M | 1 |
| Foltin, RW; Haney, M; Hart, CL; Ward, AS | 1 |
| Baldini Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Bobkiewicz-Kozłowska, T; Kus, K; Nowakowska, E | 1 |
| Bottonari, KA; Dougherty, DD; Fava, M; Fischman, AJ; Gresham, RL; Mischoulon, D; Sonawalla, SB | 1 |
| Jemal, M; Ouyang, Z | 1 |
| Born, C; Grunze, H; Marcuse, A; Schärer, LO; Walden, J | 1 |
| Gupta, S; Masand, PS | 1 |
| Ozkan, SA; Uslu, B | 1 |
| Addis, A; Bonari, L; Einarson, A; Johnson, Y; Koren, G; Matsui, D; Voyer-Lavigne, S | 1 |
| Amow, B; Borian, FE; Dunner, DL; Keller, B; Klein, D; Korenstein, SG; Manber, R; Markowitz, JC; Munsaka, M; Rush, AJ; Thase, ME; Trivedi, MH | 1 |
| Edwards, IR | 1 |
| Bate, A; Hägg, S; Spigset, O | 1 |
| Lenoci, M; Leykin, Y; Maglione, ML; Marmar, CR; Metzler, TJ; Neylan, TC; Rosenlicht, NZ; Schoenfeld, FB | 1 |
| Hackett, LP; Isbister, GK | 1 |
| Crewther, D; Crewther, S; Kiely, P; Kowal, L; Luu, C | 1 |
| Berk, M; Wynchank, D | 1 |
| Arnow, B; Blalock, JA; Blasey, C; Keller, MB; Klein, DN; Manber, R; Markowitz, JC; McCullough, JP; Riso, LP; Rothbaum, B; Rush, AJ; Thase, ME; Vivian, D | 1 |
| Bobadilla, L; Brown, ES; Dhillon, H; Frol, A; Nejtek, VA; Perantie, D | 1 |
| Campbell-Meiklejohn, D; Gorzalka, B; Hanson, L; Harrington, J; Killam, S | 1 |
| Deschênes, M; Dion, B; Tzimas, GN | 1 |
| Eckler, JR; Rabin, RA; Winter, JC | 1 |
| Bagby, RM; Grigoriadis, S; Kennedy, SH | 1 |
| Croft, HA; Labbate, LA; Oleshansky, MA | 1 |
| Nawrot, M | 1 |
| Avila, A; Bello, J; Cardona, X; Maho, P; Martin-Baranera, M; Sastre, F | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Arnow, B; Banks, P; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Howland, R; Keitner, GI; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Munsaka, M; Rothbaum, B; Rush, AJ; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M | 1 |
| Monaghan, MS; Skrabal, MZ; Stading, JA | 1 |
| Dunner, DL; Heim, CM; Keitner, G; Keller, MB; Klein, DN; Kornstein, S; McCullough, JP; Nemeroff, CB; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Weiss, PM | 1 |
| Arnow, B; Blalock, JA; Borian, FE; Castonguay, LG; Keller, MB; Klein, DN; Manber, R; Markowitz, JC; McCullough, JP; Miller, IW; Riso, LP; Rothbaum, B; Santiago, NJ; Schwartz, JE; Thase, ME; Vivian, D; Vocisano, C | 1 |
| Arnow, BA; Blalock, JA; Blasey, C; Keller, MB; Klein, DN; Manber, R; Markowitz, JC; McCullough, JP; Riso, LP; Rothbaum, BO; Rush, AJ; Thase, ME; Vivian, D | 1 |
| Choi, S | 1 |
| Jemal, M; Ouyang, Z; Wu, WW; Zhao, W; Zhu, M | 1 |
| Calderone, A; Frasure-Smith, N; Lafontaine, S; Laliberté, MA; Lespérance, F; Rouleau, JL; Talajic, M; White, M | 1 |
| Dremencov, E; Gispan-Herman, I; Mendelman, A; Overstreet, DH; Rosenstein, M; Yadid, G; Zohar, J | 1 |
| Chen, S; Hundal, KS; Joshi, N; Moore, W; Tranos, P | 1 |
| Cheng, KT; DeVane, CL; Donovan, JL; Liston, HL; Markowitz, JS; Risch, SC; Willard, L | 1 |
| Khan, IA; Siddiqui, MA | 1 |
| Ozpoyraz, N; Tamam, L | 1 |
| Fava, M; Kelly, K; Mischoulon, D; Opitz, G; Rosenbaum, JF | 1 |
| Burgess, N; Nigro, O; Shakib, S; Worthley, DL | 1 |
| Bateman, DN; Dhaun, N; Good, AM; Kelly, CA; Laing, WJ; Strachan, FE | 1 |
| Feinn, R; Hernandez-Avila, CA; Kranzler, HR; Modesto-Lowe, V | 1 |
| Ambrose, S; Bartolucci, A; Davis, LL; English, B; Farley, J; Jewell, ME; Petty, F | 1 |
| Baram, VY; Conway, CR; McGuire, JM | 1 |
| Bayles-Dazet, W; Brady, KT; Killeen, TK; McRae, AL; Mellman, TA; Sonne, SC; Timmerman, MA | 1 |
| Arnow, B; Borian, FE; Dunner, DL; Keitner, G; Keller, MB; Klein, DN; Kocsis, JH; Koran, LM; Kornstein, SG; Markowitz, JC; Rush, AJ; Trivedi, MH | 1 |
| Acebes, I; Casis, L; Echevarría, E; Micó, JA; Ortega-Alvaro, A; Saracíbar, G | 1 |
| Balboa, J; Brenlla, J; Freire-Garabal, M; García-Vallejo, LA; Núñez, MJ; Rey-Méndez, M; Rodrigo, E; Suárez, JM | 1 |
| Buclin, T; Genton, A | 1 |
| Anghelescu, I; Hautzinger, M; Lörch, B; Müller, MJ; Scheurich, A; Schläfke, D; Singer, P; Sittinger, H; Szegedi, A; Wetzel, H; Wobrock, T | 2 |
| Albert, PR; Bakish, D; Du, L; Hrdina, P; Lemonde, S | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Unsal, M; Yaris, E; Yaris, F | 1 |
| Abramov, YA; Collin, C; Hendsch, ZS; Henne, KR; Hop, CE; Kalgutkar, AS; Lame, ME; Lombardo, F; Soglia, J; Vaz, AD; Zhao, SX | 1 |
| Sasich, LD; Sukkari, SR | 1 |
| Bigal, ME; Rapoport, AM | 2 |
| Köhnlein, O; Lutz, R; Messer, T; Schmauss, M | 1 |
| Mitchell, PB | 1 |
| Arnow, B; Borian, FE; Carmody, TJ; Dunner, DL; Fawcett, J; Gelenberg, AJ; Ibrahim, HM; Jody, DN; Keitner, GI; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Nemeroff, CB; Rush, AJ; Russell, JM; Thase, ME; Trivedi, MH | 1 |
| Jahn, H; Kellner, M; Kiefer, F; Schick, M; Wiedemann, K; Yassouridis, A | 1 |
| Galanakis, P; Schreiner, R; Wiegand, MH | 1 |
| Blatman-Jan, G; Dremencov, E; Kinor, N; Newman, ME; Overstreet, DH; Schindler, CJ; Yadid, G | 1 |
| Kayumov, L; Kennedy, SH; Levitan, RD; Shapiro, CM; Shen, J | 1 |
| Ciraulo, AM; Ciraulo, DA; Greenblatt, DJ; Knapp, C; Leiderman, D; LoCastro, J; Rotrosen, J; Sarid-Segal, O | 1 |
| Camacho, LA; dos Santos, MA; Lopes, CS; Passos, SR | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Almási, J; Rihmer, Z | 1 |
| Arnow, BA; Banks, PL; Blalock, JA; Borian, FE; Howland, R; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH | 1 |
| Altshuler, LL; Burt, VK; Suri, R | 1 |
| Cassidy, EL; Lauderdale, S; Sheikh, JI | 1 |
| Baumann, P; Engel, R; Fähndrich, E; Greil, W; Hippius, H; Horvath, A; Mayland, G; Rüther, E; Schmidt, LG; Zullino, D | 1 |
| Grannemann, BD; Mahadi, S; Morris, DW; Trivedi, MH | 1 |
| Martényi, F | 1 |
| Atherton, J; Feng, B; Hanson, J; Kalgutkar, AS; Kostrubsky, SE; Kubik, R; Kulkarni, S; Mireles, R; Mutlib, AE; Strom, SC; Urda, E | 1 |
| Duczak, N; Kalgutkar, AS; Lame, ME; Peterman, SM; Soglia, JR | 1 |
| Ammar, H; Malani, AK | 1 |
| Bowman, FD; Ely, TD; Gordon, A; Gross, RE; Kelsey, JE; Kilts, CD; Knight, B; Nemeroff, CB; Newport, DJ; Selvig, A | 1 |
| Argoti, D; Bershas, D; Chen, L; Conteh, A; Liang, L; Vouros, P; Yang, E; Yu, CP | 1 |
| Blier, P; de Montigny, C; Debonnel, G; Hébert, C; Lavoie, N; Saint-André, E | 1 |
| Humphreys, WG; Ma, L; Ray, K; Sanders, M; Skiles, G; Zhang, D; Zhang, H; Zhao, W; Zhu, M | 1 |
| Clayton, AH; Montejo, AL | 1 |
| Arnow, BA; Blasey, C; Constantino, MJ; Klein, DN; Kocsis, JH; Manber, R; Markowitz, JC; Rush, AJ; Thase, ME | 1 |
| Burkhart, KK; Rasimas, JJ | 1 |
| Gibert-Rahola, J; Mico, JA; Rojas-Corrales, MO | 1 |
| Huang, MQ; Jemal, M; Mao, Y; Xia, YQ | 1 |
| Bennett, M; Chokka, P; Johnston, D; Kjernisted, K; Mancini, C; Oakman, J; Patterson, B; Van Ameringen, M; Walker, J | 1 |
| Gohdes, MA; Li, AC; Shou, WZ | 1 |
| Fava, M; Papakostas, GI | 1 |
| Blom, MB; Haffmans, PM; Hoencamp, E; Hoffman, T; Jonker, K; Spinhoven, P; van Dyck, R | 1 |
| Horst, WD; Khan, AY; Preskorn, SH | 1 |
| Lord, K | 1 |
| Dubarek, W; Kucia, K | 1 |
| Blom, MB; Dusseldorp, E; Haffmans, J; Hoencamp, E; Jonker, K; Spinhoven, P; van Dyck, R | 1 |
| Jemal, M; Wu, ST; Xia, YQ | 1 |
| Jiang, XY; Li, AC; Mai, TT; Shou, WZ | 1 |
| Olivier, B; Schweitzer, DH; Waldinger, MD; Zwinderman, AH | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Bauman, JN; Cox, LM; Frederick, KS; Kalgutkar, AS; Obach, RS; Sawant, A; Walsky, RL | 1 |
| Dunn, MC; Dykens, JA; Jamieson, JD; Marroquin, LD; Nadanaciva, S; Smith, AR; Will, Y; Xu, JJ | 1 |
| Arnow, BA; Gelenberg, AJ; Keller, ME; Klein, DN; Kocsis, JH; Kraemer, HC; Manber, R; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH | 1 |
| Collins, SC; Eliasson, L; Olofsson, CS; Rorsman, P; Salehi, A | 1 |
| Kelly, BD | 1 |
| Kalgutkar, AS; Obach, RS; Soglia, JR; Zhao, SX | 1 |
| Budney, A; el-Guebaly, N; Elkashef, A; Gruber, A; Haney, M; Huestis, M; Vocci, F | 1 |
| Arnow, B; Klein, DN; Kocsis, JH; Leon, AC; Manber, R; Markowitz, JC; Thase, ME | 1 |
| Arnow, BA; Blalock, JA; Keitner, GI; Klein, DN; Maddux, RE; Manber, R; Markowitz, JC; Riso, LP; Rothbaum, BO; Thase, ME | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, S | 1 |
| Arnow, BA; Carmody, TJ; Denton, WH; Keller, MB; Klein, DN; Rush, AJ; Thase, ME; Trivedi, MH | 1 |
| Bonner, R; Kalgutkar, AS; Mu, L; Schneider, RP; Zhang, H | 1 |
| Erickson, D; Hagan, JB; Singh, RJ | 1 |
| Crits-Christoph, P; Klein, DN; Manber, R; Stulz, N; Thase, ME | 1 |
| Blom, MB; Hoek, HW; Hoencamp, E; Judith Haffmans, PM; Spinhoven, P; van Dyck, R | 1 |
| Brown, CS; Moll, JL | 1 |
| Aubry, JM; Bertschy, G; Bondolfi, G; Gex-Fabry, M; Kosel, M; Malafosse, A; Perroud, N; Uher, R | 1 |
| Dubois, J; Vanrullen, R | 1 |
| Bisaga, A; Cheng, WY; Horey, JT; Levin, FR; Mariani, JJ; Nunes, E; Sullivan, M | 1 |
| Arnow, BA; Constantino, MJ; Klein, DN; Laws, HB; Manber, R; Rothbaum, BO | 1 |
| Goldberg, JF | 1 |
| Eun, CJ; Han, E; Kim, JA; Song, JM; Tak, YK | 1 |
| Ford, KA | 1 |
| Muller, CD; Peluso, J; Saab, L; Ubeaud-Sequier, G | 1 |
| Arnow, BA; Blasey, C; Klein, DN; Kocsis, JH; Manber, R; Markowitz, JC; Rothbaum, BO; Steidtmann, D; Thase, ME | 1 |
| Bae, MA; Chae, CH; Chung, HC; Kim, KS; Lee, HA; Lee, JY; Park, MJ; Park, SJ; Shin, DS; Yoo, DS | 1 |
| Davis, K; Fabian, E; Greenhaw, J; Groeters, S; Herold, M; Kamp, H; Looser, R; Marxfeld, H; Mattes, W; Mellert, W; Moeller, N; Montoya-Parra, G; Prokoudine, A; Strauss, V; van Ravenzwaay, B; Walk, T | 1 |
| Brownlow, JA; Harb, GC; Ross, RJ | 1 |
| Kakuni, M; Kamimura, H; Kato, K; Kawamura, A; Kazuki, Y; Nakada, N; Ohbuchi, M; Oshimura, M; Sato, K; Tateno, C; Usui, T | 1 |
| Isin, EM; Mettetal, JT; Ogese, MO; Thompson, RA; Williams, DP | 1 |
| Choi, SW; Kim, KS; Kim, SJ; Lee, HA; Lee, S | 1 |
| Hoge, CW; Lee, DJ; Rasmusson, AM; Schnitzlein, CW; Vythilingam, M; Wolf, JP | 1 |
| Barbosa, IA; Beltrão, N; Cunha-Oliveira, T; Oliveira, PJ; Santos, R; Seabra, C; Silva, AM; Vega-Naredo, I | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Chen, S; Doshi, U; Guo, L; Li, AP; Ren, Z; Zhang, J | 1 |
| Burkina, V; Pilipenko, N; Sakalli, S; Zamaratskaia, G; Zlabek, V | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 1 |
| Artursson, P; Baranczewski, P; Filppula, AM; Mateus, A; Parvizi, R | 1 |
| Aslamkhan, AG; Gonzalez, R; Imredy, J; Kaczor, A; Kuhls, M; Lebron, J; Liaw, A; Liu, L; Mitra, K; Pearson, K; Ruth, M; Sistare, FD; Vu, H; Wei, C; Xu, Q; Yu, Y | 1 |
| Gai, Z; Häusler, S; Krajnc, E; Kullak-Ublick, GA; Samodelov, SL; Stieger, B; Visentin, M | 1 |
| Alluri, RV; Basu, S; Dodd, S; Emami Riedmaier, A; Huckle, JE; Parrott, N; Pepin, XJH | 1 |
| Balasubramanian, R; Maideen, NMP | 1 |
| Ahn, J; Ahn, JH; Cho, HS; Choi, MS; Han, HY; Jegal, H; Kim, S; Oh, JH; Park, SM; Yoon, S | 1 |
| Li, AP; Wei, H | 1 |
71 review(s) available for triazoles and nefazodone
| Article | Year |
|---|---|
Nefazodone: preclinical pharmacology of a new antidepressant.
Topics: Animals; Antidepressive Agents; Piperazines; Triazoles | 1990 |
Nefazodone and venlafaxine: two new agents for the treatment of depression.
Topics: Antidepressive Agents; Consumer Product Safety; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Family Practice; Humans; Norepinephrine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1995 |
New antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Fluvoxamine; Humans; Piperazines; Triazoles | 1995 |
The potential benefits of serotonin receptor-specific agents.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Humans; Isoxazoles; Ondansetron; Piperazines; Piperidines; Receptors, Serotonin; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Sumatriptan; Triazoles | 1994 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Nociceptors; Piperazines; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Serotonin; Triazoles | 1995 |
Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Piperazines; Placebos; Psychomotor Agitation; Randomized Controlled Trials as Topic; Triazoles | 1995 |
Evolutionary trends in the pharmacotherapeutic management of depression.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Child; Clinical Trials as Topic; Cyclohexanols; Decision Trees; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Humans; Piperazines; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 1994 |
Novel serotonergic mechanisms and clinical experience with nefazodone.
Topics: Antidepressive Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Piperazines; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Triazoles | 1993 |
Efficacy in long-term treatment of depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Humans; Imipramine; Long-Term Care; Piperazines; Placebos; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Treatment Outcome; Triazoles | 1996 |
The safety profile of nefazodone.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Mixed Function Oxygenases; Piperazines; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome; Triazoles; Weight Gain | 1996 |
Tolerability and safety: essentials in antidepressant pharmacotherapy.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Dizziness; Drug Overdose; Humans; Incidence; Nausea; Patient Dropouts; Piperazines; Placebos; Sleep; Treatment Outcome; Triazoles; Xerostomia | 1996 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Disorder; Diagnosis, Differential; Electroconvulsive Therapy; Female; Humans; Lithium; Male; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 1996 |
Nefazodone: a new antidepressant.
Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Triazoles | 1995 |
New antidepressant drugs and the treatment of depression in the medically ill patient.
Topics: Adjustment Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Drug Interactions; Humans; Patient Care Team; Piperazines; Selective Serotonin Reuptake Inhibitors; Sick Role; Triazoles; Venlafaxine Hydrochloride | 1996 |
Nefazodone: its place among antidepressants.
Topics: Antidepressive Agents, Second-Generation; Controlled Clinical Trials as Topic; Drug Interactions; Humans; Piperazines; Triazoles | 1996 |
Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Triazoles | 1997 |
Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1996 |
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbidity; Depressive Disorder; Diagnosis, Differential; Female; Humans; Mental Disorders; Panic Disorder; Piperazines; Premenstrual Syndrome; Psychotherapy; Risk Factors; Sertraline; Sodium Lactate; Triazoles | 1997 |
Antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1997 |
Safety and tolerability of the new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Headache; Humans; Mianserin; Mirtazapine; Nausea; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Triazoles; Venlafaxine Hydrochloride | 1997 |
Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.
Topics: Aged; Aging; Antidepressive Agents; Benzamides; Cyclohexanols; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1997 |
Clinical pharmacokinetics of nefazodone.
Topics: Adult; Age Factors; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Female; Humans; Kidney Diseases; Liver Diseases; Male; Piperazines; Sex Factors; Triazoles | 1997 |
Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Dopamine; Humans; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Receptors, Neurotransmitter; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Triazoles; Venlafaxine Hydrochloride | 1998 |
Antidepressant-induced sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Libido; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Triazoles | 1998 |
New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Depressive Disorder; Humans; Isoenzymes; Mianserin; Mirtazapine; Piperazines; Risk Factors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Pharmacokinetic interactions of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Depressive Disorder; Drug Prescriptions; Humans; Monoamine Oxidase Inhibitors; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Fluoxetine. A pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Health Care Costs; Humans; Piperazines; Quality of Life; Selective Serotonin Reuptake Inhibitors; Triazoles | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Piperazines; Triazoles; Venlafaxine Hydrochloride | 1998 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 1999 |
Care of the sexually active depressed patient.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Humans; Mianserin; Mirtazapine; Piperazines; Sexual Dysfunctions, Psychological; Triazoles | 1999 |
Pharmacokinetic considerations of antidepressant use in the elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Biotransformation; Bupropion; Creatinine; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Female; Half-Life; Humans; Intestinal Absorption; Liver; Male; Middle Aged; Piperazines; Triazoles; Venlafaxine Hydrochloride | 1999 |
New approaches to the treatment of refractory depression.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Pindolol; Piperazines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Triazoles; Triiodothyronine | 2000 |
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Morpholines; Piperazines; Reboxetine; Structure-Activity Relationship; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2000 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up Studies; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2000 |
New strategies for treating chronic depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Humans; Piperazines; Treatment Outcome; Triazoles | 2000 |
The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration.
Topics: Antidepressive Agents, Second-Generation; Biological Availability; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Piperazines; Somatoform Disorders; Treatment Outcome; Triazoles | 2000 |
The effects of antidepressants on sexual functioning in depressed patients: a review.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Sexuality; Single-Blind Method; Triazoles | 2001 |
Clinical significance of monitoring early symptom change to predict outcome.
Topics: Algorithms; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Mental Disorders; Piperazines; Probability; Prognosis; Recurrence; Remission Induction; Severity of Illness Index; Terminology as Topic; Treatment Outcome; Triazoles | 2001 |
Acute and maintenance treatment of chronic depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Dysthymic Disorder; Humans; Multicenter Studies as Topic; Piperazines; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Triazoles | 2001 |
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Controlled Clinical Trials as Topic; Depressive Disorder; Female; Humans; Imipramine; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome; Triazoles; Weight Gain | 2001 |
Pharmacology of antidepressants: focus on nefazodone.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Triazoles | 2002 |
Clinical use of nefazodone in major depression: a 6-year perspective.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Hospitalization; Humans; Meta-Analysis as Topic; Piperazines; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sleep; Triazoles | 2002 |
Overview of psychiatric disorders and the role of newer antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Humans; Mental Disorders; Piperazines; Sleep Wake Disorders; Triazoles | 2002 |
Six-year perspectives on the safety and tolerability of nefazodone.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Body Weight; Chronic Disease; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male; Obesity; Piperazines; Priapism; Seizures; Sexual Dysfunctions, Psychological; Suicide; Triazoles | 2002 |
Cost savings with nefazodone in treating depression.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cost Savings; Depressive Disorder; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Hypnotics and Sedatives; Piperazines; Sleep Wake Disorders; Triazoles | 2002 |
Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Topics: Bupropion; Dronabinol; Eating; HIV Seropositivity; Humans; Marijuana Smoking; Piperazines; Substance Withdrawal Syndrome; Triazoles | 2002 |
[Pharmacological justification for the use of new antidepressant drugs].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Piperazines; Triazoles; Venlafaxine Hydrochloride | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Triazoles; Venlafaxine Hydrochloride; Weight Gain | 2002 |
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin; Drug Tolerance; Erectile Dysfunction; Humans; Male; Mianserin; Mirtazapine; Moclobemide; Orgasm; Piperazines; Remission, Spontaneous; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Triazoles | 2003 |
Disorders of motion and depth.
Topics: Alzheimer Disease; Amblyopia; Antidepressive Agents; Cerebral Veins; Cues; Depth Perception; Epilepsy; Humans; Mesencephalon; Motion Perception; Occipital Lobe; Perceptual Disorders; Piperazines; Schizophrenia; Sinus Thrombosis, Intracranial; Temporal Lobe; Triazoles; Vestibular Diseases; Williams Syndrome | 2003 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Preventive migraine therapy: what is new.
Topics: Analgesics; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Antioxidants; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins; Clonidine; Coenzymes; Fructose; Humans; Lisinopril; Migraine Disorders; Neuroprotective Agents; Petasites; Phytotherapy; Piperazines; Tetrazoles; Topiramate; Triazoles; Ubiquinone | 2004 |
Therapeutic drug monitoring of non-tricyclic antidepressant drugs.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Monitoring; Humans; Mianserin; Piperazines; Selective Serotonin Reuptake Inhibitors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Migraine preventive therapy: current and emerging treatment options.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Calcium Channel Blockers; Coenzymes; Drug Therapy; Humans; Levetiracetam; Lisinopril; Migraine Disorders; Petasites; Piperazines; Piracetam; Preventive Medicine; Triazoles; Ubiquinone | 2005 |
[Three paradigms in the treatment of posttraumatic stress disorder].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Combat Disorders; Controlled Clinical Trials as Topic; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Stress Disorders, Traumatic, Acute; Triazoles | 2005 |
Major depressive disorder, antidepressants, and sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Sexual Dysfunctions, Psychological; Triazoles | 2006 |
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Trazodone; Triazoles | 2007 |
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Depressive Disorder; Humans; Liver Diseases; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Risk Factors; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
Marijuana neurobiology and treatment.
Topics: Brain; Buspirone; Cannabis; Cognitive Behavioral Therapy; Dronabinol; Humans; Marijuana Abuse; Narcotic Antagonists; Piperazines; Social Facilitation; Triazoles | 2008 |
The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature.
Topics: Antidepressive Agents, Second-Generation; Apomorphine; Biogenic Monoamines; Central Nervous System Stimulants; Dopamine Agonists; Evidence-Based Medicine; Humans; Piperazines; Sexual Dysfunction, Physiological; Sexuality; Triazoles | 2011 |
Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Dreams; Eye Movement Desensitization Reprocessing; Fluvoxamine; Humans; Piperazines; Prazosin; REM Sleep Behavior Disorder; Restless Legs Syndrome; Serotonin and Noradrenaline Reuptake Inhibitors; Sleep; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Stress Disorders, Post-Traumatic; Trazodone; Triazoles | 2015 |
Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Pharmaceutical Preparations; Piperazines; Risk Assessment; Triazoles | 2016 |
Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bupropion; Chronic Pain; Humans; Mianserin; Mirtazapine; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Thiazoles; Trazodone; Triazoles | 2016 |
PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS.
Topics: Antidepressive Agents; Combined Modality Therapy; Humans; Piperazines; Psychotherapy; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
Topics: Anti-Infective Agents; Anticonvulsants; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Colchicine; Contraceptives, Oral; Cytochrome P-450 CYP3A; Drug Interactions; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Organic Anion Transporters; Phosphodiesterase 5 Inhibitors; Piperazines; Triazoles; Warfarin | 2021 |
150 trial(s) available for triazoles and nefazodone
| Article | Year |
|---|---|
Symptom comorbidity in anxiety and depressive disorders.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Panic; Personality Assessment; Piperazines; Psychometrics; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles | 1990 |
Placebo-controlled dose-ranging trial designs in phase II development of nefazodone.
Topics: Depressive Disorder; Double-Blind Method; Humans; Piperazines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Serotonin Antagonists; Triazoles | 1990 |
A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Piperazines; Randomized Controlled Trials as Topic; Triazoles | 1989 |
Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.
Topics: Adult; Anticoagulants; Antidepressive Agents; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Humans; Male; Piperazines; Tablets; Triazoles; Warfarin | 1995 |
A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 1995 |
Nefazodone: aspects of efficacy.
Topics: Ambulatory Care; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Humans; Imipramine; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Survival Analysis; Treatment Outcome; Triazoles | 1995 |
Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects.
Topics: Adult; Aged; Aging; Antidepressive Agents; Automobile Driving; Cognition; Double-Blind Method; Humans; Imipramine; Multivariate Analysis; Piperazines; Psychomotor Performance; Reaction Time; Reference Values; Sleep; Triazoles | 1995 |
The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Buspirone; Double-Blind Method; Humans; Male; Penile Erection; Piperazines; Reference Values; Sleep; Trazodone; Triazoles | 1994 |
Long-term treatment of depression with nefazodone.
Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder; Double-Blind Method; Humans; Imipramine; Piperazines; Triazoles | 1994 |
Controlled comparison of nefazodone and amitriptyline in major depressive inpatients.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Triazoles | 1994 |
Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses.
Topics: Adolescent; Adult; Antidepressive Agents; Female; Humans; Liver Diseases; Male; Middle Aged; Piperazines; Triazoles | 1994 |
Nefazodone and imipramine in major depression: a placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Triazoles | 1994 |
Nefazodone in the treatment of premenstrual syndrome: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Drug Administration Schedule; Female; Humans; Piperazines; Premenstrual Syndrome; Triazoles | 1994 |
A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Patient Compliance; Patient Dropouts; Piperazines; Placebos; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Triazoles | 1994 |
Neuroendocrine and temperature effects of nefazodone in healthy volunteers.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Body Temperature; Dose-Response Relationship, Drug; Humans; Hydrocortisone; Male; Middle Aged; Piperazines; Placebos; Prolactin; Single-Blind Method; Triazoles | 1993 |
The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects.
Topics: Adolescent; Adult; Antidepressive Agents; Body Temperature; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Electroencephalography; Ethanol; Female; Hemodynamics; Humans; Imipramine; Male; Memory; Piperazines; Psychomotor Performance; Reference Values; Triazoles | 1993 |
Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Antidepressive Agents; Chromatography, High Pressure Liquid; Cimetidine; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Humans; Male; Middle Aged; Piperazines; Triazoles | 1995 |
Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.
Topics: Adult; Antidepressive Agents, Second-Generation; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Digestive System; Humans; Intestinal Absorption; Intubation, Gastrointestinal; Male; Piperazines; Serotonin Receptor Agonists; Spectrophotometry, Ultraviolet; Triazoles | 1995 |
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Community Mental Health Services; Comorbidity; Depressive Disorder; Drug Administration Schedule; Family Practice; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome; Triazoles | 1996 |
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 1996 |
Nefazodone in the treatment of severe, melancholic, and recurrent depression.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.
Topics: 1-Naphthylamine; Adolescent; Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Orgasm; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Behavior; Treatment Outcome; Triazoles | 1996 |
Therapeutic dose range of nefazodone in the treatment of major depression.
Topics: Age Factors; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Piperazines; Treatment Outcome; Triazoles | 1996 |
Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Antidepressive Agents, Second-Generation; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Heart Rate; Humans; Male; Piperazines; Propranolol; Triazoles | 1995 |
An open-label trial of nefazodone in high comorbidity panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder; Female; Humans; Male; Middle Aged; Panic Disorder; Piperazines; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease.
Topics: Antidepressive Agents; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lung Diseases, Obstructive; Male; Piperazines; Theophylline; Triazoles | 1995 |
Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation.
Topics: Adult; Antidepressive Agents, Second-Generation; Biotransformation; Chromatography, High Pressure Liquid; Humans; Hydroxylation; Male; Piperazines; Spectrophotometry, Ultraviolet; Triazoles | 1996 |
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Male; Piperazines; Triazoles | 1995 |
Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Lorazepam; Male; Piperazines; Triazoles | 1995 |
Economic analysis of treating depression with nefazodone v. imipramine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; England; Humans; Imipramine; Models, Economic; Piperazines; Recurrence; Treatment Outcome; Triazoles; Wales | 1996 |
Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening.
Topics: Adult; Antidepressive Agents; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Half-Life; Humans; Male; Piperazines; Triazoles | 1996 |
Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lorazepam; Male; Mental Recall; Metabolic Clearance Rate; Piperazines; Psychomotor Performance; Triazolam; Triazoles | 1995 |
Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Mixed Function Oxygenases; Piperazines; Triazolam; Triazoles | 1995 |
A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.
Topics: Adolescent; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Biotransformation; Female; Half-Life; Humans; Male; Middle Aged; Piperazines; Sex Characteristics; Triazoles | 1996 |
Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Biotransformation; Double-Blind Method; Drug Interactions; Half-Life; Haloperidol; Humans; Male; Piperazines; Psychomotor Performance; Triazoles | 1996 |
Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers.
Topics: Adult; Antidepressive Agents, Second-Generation; Cardiotonic Agents; Cross-Over Studies; Digoxin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Electrocardiography; Heart Rate; Humans; Male; Piperazines; Triazoles | 1996 |
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Double-Blind Method; Electroencephalography; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 1996 |
The lack effect of food on the bioavailability of nefazodone tablets.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Biological Availability; Cross-Over Studies; Dietary Fats; Humans; Male; Piperazines; Reference Values; Tablets; Triazoles | 1996 |
Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Dextromethorphan; Humans; Phenotype; Piperazines; Triazoles | 1996 |
An open trial of nefazodone in adult patients with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Triazoles | 1996 |
Curvaceous model of recovery from depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder; Humans; Models, Statistical; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 1997 |
Case study: nefazodone for juvenile mood disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Female; Humans; Male; Mood Disorders; Piperazines; Treatment Outcome; Triazoles | 1997 |
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Sleep, REM; Triazoles | 1997 |
A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
Topics: Adult; Affect; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Polysomnography; Psychiatric Status Rating Scales; Sleep; Sleep Wake Disorders; Treatment Outcome; Triazoles | 1997 |
Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Double-Blind Method; Humans; Hydrocortisone; Hypothermia; Male; Middle Aged; Paroxetine; Piperazines; Pyrimidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Triazoles | 1997 |
Nefazodone and REM sleep: how do antidepressant drugs decrease REM sleep?
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Piperazines; Serotonin; Sleep Stages; Sleep, REM; Triazoles | 1998 |
Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles | 1998 |
A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
Topics: Adult; Age of Onset; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Headache; Hospitalization; Humans; Linear Models; Male; Nausea; Piperazines; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Triazoles | 1998 |
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Circadian Rhythm; Comorbidity; Depressive Disorder; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Initiation and Maintenance Disorders; Sleep, REM; Triazoles; Wakefulness | 1998 |
Open trial of nefazodone for combat-related posttraumatic stress disorder.
Topics: Adult; Ambulatory Care; Anger; Antidepressive Agents, Second-Generation; Combat Disorders; Depressive Disorder; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Psychiatric Status Rating Scales; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 1998 |
Nefazodone for social phobia: a clinical case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Phobic Disorders; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 1998 |
Nefazodone in social phobia.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Administration Schedule; Female; Humans; Male; Phobic Disorders; Piperazines; Psychiatric Status Rating Scales; Serotonin Agents; Treatment Outcome; Triazoles | 1999 |
Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lithium; Male; Photometry; Piperazines; Triazoles | 1999 |
Nefazodone in post-traumatic stress disorder: results from six open-label trials.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Piperazines; Predictive Value of Tests; Stress Disorders, Post-Traumatic; Triazoles | 1999 |
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Female; HIV Seropositivity; Humans; Male; Patient Dropouts; Piperazines; Protease Inhibitors; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Triazoles | 1999 |
Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Recurrence; Triazoles | 1999 |
Nefazodone for patients with chronic fatigue syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged; Piperazines; Sleep Wake Disorders; Treatment Outcome; Triazoles | 1999 |
Nefazodone treatment and dream reports in chronic PTSD.
Topics: Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combat Disorders; Dreams; Female; Humans; Male; Middle Aged; Piperazines; Sleep, REM; Triazoles | 1999 |
Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Treatment Failure; Triazoles | 1999 |
Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Male; Periodicity; Piperazines; Placebos; Polysomnography; Single-Blind Method; Sleep; Sleep Initiation and Maintenance Disorders; Sleep, REM; Substance Withdrawal Syndrome; Triazoles | 1999 |
The effect of nefazodone on clozapine plasma concentrations.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Humans; Male; Piperazines; Triazoles | 1999 |
Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Serotonin Antagonists; Triazoles | 1999 |
Rapid fade of antidepressant effect of nefazodone in bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Placebo Effect; Recurrence; Research Design; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
Pilot open-label study of nefazodone in panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Panic Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Triazoles | 1999 |
Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder.
Topics: Adult; Antidepressive Agents; Cohort Studies; Combat Disorders; Disasters; Female; Fluoxetine; Fluvoxamine; Humans; Lamotrigine; Male; Middle Aged; Personality Inventory; Piperazines; Psychometrics; Rape; Reproducibility of Results; Stress Disorders, Post-Traumatic; Triazines; Triazoles | 1999 |
Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Piperazines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Triazoles | 2000 |
Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychotherapy, Group; Treatment Outcome; Triazoles | 2000 |
Nefazodone treatment for chronic posttraumatic stress disorder: an open trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combat Disorders; Female; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles; Veterans | 2000 |
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Female; Humans; Male; Piperazines; Treatment Outcome; Triazoles | 2000 |
Nefazodone in patients with treatment-refractory posttraumatic stress disorder.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; Circadian Rhythm; Combat Disorders; Comorbidity; Drug Administration Schedule; Drug Resistance; Humans; Male; Mental Disorders; Piperazines; Psychiatric Status Rating Scales; Severity of Illness Index; Sexual Behavior; Sleep; Social Adjustment; Stress Disorders, Post-Traumatic; Triazoles; Veterans | 2000 |
Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Mental Disorders; Middle Aged; Minnesota; Obsessive-Compulsive Disorder; Paraphilic Disorders; Piperazines; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Triazoles | 2000 |
Nefazodone treatment of adolescent depression: an open-label study of response and biochemistry.
Topics: Adolescent; Adolescent Behavior; Adolescent Psychiatry; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Piperazines; Serotonin; Treatment Outcome; Triazoles | 2000 |
Nefazodone pharmacokinetics in depressed children and adolescents.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Area Under Curve; Child; Cytochrome P-450 CYP2D6; Depressive Disorder; Female; Half-Life; Humans; Male; Piperazines; Treatment Outcome; Triazoles | 2000 |
Does nefazadone alone, the cognitive behavioral-analysis system of psychotherapy, or the combination of both work best for patients with chronic depression?
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Humans; Middle Aged; Piperazines; Triazoles | 2000 |
Efficacy of open-label nefazodone treatment in patients with panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Panic Disorder; Piperazines; Psychiatric Status Rating Scales; Time Factors; Triazoles | 2000 |
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Depressive Disorder; Female; Humans; Incidence; Male; Mental Disorders; Middle Aged; Panic Disorder; Piperazines; Prospective Studies; Remission, Spontaneous; Severity of Illness Index; Sex Factors; Sexual Behavior; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2001 |
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Recurrence; Sertraline; Sexual Dysfunctions, Psychological; Treatment Outcome; Triazoles | 2001 |
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Histamine H1 Antagonists; Humans; Linear Models; Loratadine; Male; Middle Aged; Piperazines; Terfenadine; Triazoles | 2001 |
Which depressed patients respond to nefazodone and when?
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Logistic Models; Male; Patient Selection; Personality Inventory; Piperazines; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome; Triazoles | 2001 |
Nefazodone for chronic daily headache prophylaxis: an open-label study.
Topics: Adolescent; Adult; Analgesics; Child; Chronic Disease; Female; Headache; Humans; Male; Medical Records; Middle Aged; Piperazines; Triazoles | 2001 |
Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Paroxetine; Piperazines; Placebos; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 2001 |
Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Hispanic or Latino; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2001 |
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
Topics: Adult; Buspirone; Double-Blind Method; Female; Humans; Piperazines; Premenstrual Syndrome; Psychiatric Status Rating Scales; Receptors, Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Triazoles | 2001 |
The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antidepressive Agents; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pindolol; Piperazines; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Triazoles; Tryptophan | 2001 |
Opposite effects of nefazodone in two human models of anxiety.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Conditioning, Psychological; Female; Galvanic Skin Response; Humans; Male; Piperazines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Speech; Statistics, Nonparametric; Triazoles | 2001 |
Open trial of nefazodone for combat veterans with posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Combat Disorders; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Triazoles; Veterans | 2001 |
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome; Triazoles | 2001 |
Treatment of somatization disorder with nefazodone: a prospective, open-label study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Somatoform Disorders; Treatment Outcome; Triazoles | 2001 |
An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder.
Topics: Arousal; Combat Disorders; Depressive Disorder, Major; Dreams; Electroencephalography; Humans; Male; Middle Aged; Piperazines; Polysomnography; Sleep Stages; Treatment Outcome; Triazoles; Veterans | 2001 |
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Social Adjustment; Treatment Outcome; Triazoles | 2002 |
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2002 |
Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 2002 |
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Drug Administration Schedule; Female; Humans; Linear Models; Male; Outcome Assessment, Health Care; Personality Inventory; Piperazines; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2002 |
Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Triazoles | 2002 |
Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory.
Topics: Adult; Amitriptyline; Antidepressive Agents; Attention; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Electrooculography; Evoked Potentials; Female; Humans; Male; Memory; Neuropsychological Tests; Paroxetine; Piperazines; Reaction Time; Task Performance and Analysis; Triazoles | 2002 |
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Female; Humans; Male; Personal Satisfaction; Piperazines; Psychiatric Status Rating Scales; Sex Factors; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome; Triazoles | 2002 |
Nefazodone decreases anxiety during marijuana withdrawal in humans.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Arousal; Attention; Dose-Response Relationship, Drug; Female; Humans; Male; Marijuana Abuse; Neuropsychological Tests; Piperazines; Psychomotor Performance; Sleep; Substance Withdrawal Syndrome; Triazoles | 2003 |
Nefazodone treatment of pathological gambling: a prospective open-label controlled trial.
Topics: Adult; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gambling; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Serotonin Antagonists; Treatment Outcome; Triazoles | 2002 |
Nefazodone in psychotic unipolar and bipolar depression: a retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy.
Topics: Antidepressive Agents, Second-Generation; Female; Follow-Up Studies; Humans; Piperazines; Pregnancy; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects; Prospective Studies; Surveys and Questionnaires; Trazodone; Triazoles | 2003 |
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Psychotherapy; Severity of Illness Index; Sleep Wake Disorders; Triazoles | 2003 |
The effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Polysomnography; Psychiatric Status Rating Scales; Sleep; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Treatment Outcome; Triazoles; Veterans | 2003 |
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Piperazines; Receptors, Serotonin, 5-HT2; Schizophrenia; Serotonin Antagonists; Substance-Related Disorders; Triazoles | 2003 |
Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Interpersonal Relations; Learning; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2003 |
Open-label nefazodone in patients with a major depressive episode and alcohol dependence.
Topics: Adult; Affect; Alcoholism; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Memory; Middle Aged; Piperazines; Treatment Outcome; Triazoles | 2003 |
A comparison of antidepressant response in younger and older women.
Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Sertraline; Sex Characteristics; Triazoles | 2003 |
Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.
Topics: Aged; Analysis of Variance; Depression; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Prospective Studies; Single-Blind Method; Triazoles | 2003 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Eligibility Determination; Female; Humans; Male; Middle Aged; Piperazines; Psychotherapy; Recurrence; Substance Withdrawal Syndrome; Triazoles | 2003 |
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Ketoconazole; Male; Midazolam; Piperazines; Triazoles | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disease; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Triazoles | 2003 |
Therapeutic alliance in depression treatment: controlling for prior change and patient characteristics.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Piperazines; Professional-Patient Relations; Recurrence; Triazoles | 2003 |
Therapeutic reactance as a predictor of outcome in the treatment of chronic depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Defense Mechanisms; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Internal-External Control; Male; Middle Aged; Motivation; Personality Inventory; Piperazines; Psychometrics; Treatment Outcome; Triazoles | 2003 |
Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.
Topics: Adrenal Cortex; Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Glucocorticoids; Humans; Hydrocortisone; Male; Methylprednisolone; Piperazines; Reference Values; Triazoles | 2003 |
An open-label study of nefazodone treatment of major depression in patients with congestive heart failure.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Electrocardiography; Electrocardiography, Ambulatory; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Piperazines; Severity of Illness Index; Surveys and Questionnaires; Triazoles | 2003 |
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
Topics: Administration, Oral; Adult; Alprazolam; Area Under Curve; Breath Tests; Carbon Radioisotopes; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Administration Schedule; Erythromycin; Fluoxetine; Half-Life; Humans; Male; Middle Aged; Molecular Probes; Piperazines; Sertraline; Triazoles; Venlafaxine Hydrochloride | 2004 |
Nefazodone treatment of comorbid alcohol dependence and major depression.
Topics: Adult; Alcoholism; Analysis of Variance; Chi-Square Distribution; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Triazoles | 2004 |
A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study.
Topics: Adult; Aged; Analysis of Variance; Combat Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Sex Offenses; Stress Disorders, Post-Traumatic; Triazoles; Veterans | 2004 |
Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Sertraline; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2004 |
Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Observer Variation; Piperazines; Triazoles | 2003 |
[Combination treatment with SSRI and cognitive behavior therapy for relapse prevention of alcohol-dependent men. Results of a randomized, controlled multicenter therapeutic study].
Topics: Adult; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disease-Free Survival; Germany; Humans; Male; Middle Aged; Piperazines; Prevalence; Risk Assessment; Risk Factors; Secondary Prevention; Treatment Outcome; Triazoles | 2005 |
Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study.
Topics: Adult; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Counseling; Diagnosis, Computer-Assisted; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome; Triazoles | 2004 |
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Self-Assessment; Treatment Outcome; Triazoles | 2005 |
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Cortodoxone; Dehydroepiandrosterone; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Male; Metyrapone; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2004 |
Nefazodone in primary insomnia: an open pilot study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Patient Dropouts; Pilot Projects; Piperazines; Polysomnography; Psychiatric Status Rating Scales; Sleep Initiation and Maintenance Disorders; Triazoles | 2004 |
The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Administration Schedule; Female; Humans; Middle Aged; Piperazines; Polysomnography; Seasonal Affective Disorder; Sleep Stages; Surveys and Questionnaires; Triazoles | 2005 |
Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.
Topics: Adult; Antidepressive Agents, Second-Generation; Cocaine-Related Disorders; Depressive Disorder; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Triazoles | 2005 |
Nefazodone in out-patient treatment of inhaled cocaine dependence: a randomized double-blind placebo-controlled trial.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Cocaine-Related Disorders; Double-Blind Method; Humans; Middle Aged; Piperazines; Triazoles | 2005 |
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Cross-Over Studies; Depressive Disorder, Major; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Regression Analysis; Survival Analysis; Treatment Outcome; Triazoles | 2005 |
Mixed anxiety and depression in older adults: clinical characteristics and management.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2005 |
Symptom clusters as predictors of late response to antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Principal Component Analysis; Prognosis; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2005 |
The neural correlates of social anxiety disorder and response to pharmacotherapy.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Brain Mapping; Case-Control Studies; Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Regional Blood Flow; Social Behavior Disorders; Statistics as Topic; Triazoles | 2006 |
Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Blood Platelets; Blood Pressure; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Piperazines; Reference Values; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Triazoles; Tyramine; Venlafaxine Hydrochloride | 2007 |
Dropouts versus completers among chronically depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Patient Dropouts; Physician-Patient Relations; Piperazines; Risk Factors; Triazoles | 2007 |
Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Humans; Male; Phobic Disorders; Piperazines; Treatment Outcome; Triazoles | 2007 |
Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Interpersonal Relations; Male; Personality Disorders; Piperazines; Psychotherapy; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2007 |
Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Desipramine; Drug Interactions; Female; Humans; Male; Middle Aged; Piperazines; Triazoles | 2007 |
Combination treatment for acute depression is superior only when psychotherapy is added to medication.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Interpersonal Relations; Male; Piperazines; Psychotherapy; Triazoles | 2007 |
Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Patient Participation; Personality Inventory; Piperazines; Triazoles | 2009 |
Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination.
Topics: Adaptation, Psychological; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Culture; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Personality Disorders; Personality Inventory; Piperazines; Problem Solving; Recurrence; Triazoles | 2009 |
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
Topics: Adult; Affect; Algorithms; Antidepressive Agents, Second-Generation; Delta Rhythm; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Ambulatory; Paroxetine; Piperazines; Signal Processing, Computer-Assisted; Sleep; Sleep, REM; Treatment Outcome; Triazoles | 2009 |
Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Marriage; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Self Disclosure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Differential effects of treatments for chronic depression: a latent growth model reanalysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Models, Psychological; Personality Inventory; Piperazines; Psychometrics; Secondary Prevention; Triazoles | 2010 |
Treatment of depression in patients from ethnic minority groups in the Netherlands.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cross-Cultural Comparison; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morocco; Netherlands; Piperazines; Psychotherapy; Suriname; Triazoles; Turkey | 2010 |
Comparison of substance use milestones in cannabis- and cocaine-dependent patients.
Topics: Adult; Age of Onset; Amines; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Marijuana Abuse; Piperazines; Triazoles; Young Adult | 2012 |
The relation between changes in patients' interpersonal impact messages and outcome in treatment for chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Female; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2012 |
A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Treatment Outcome; Triazoles | 2013 |
Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression.
Topics: Adult; Antidepressive Agents; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Triazoles | 2013 |
240 other study(ies) available for triazoles and nefazodone
| Article | Year |
|---|---|
Potentiation of opioid analgesia by the antidepressant nefazodone.
Topics: Analgesia; Animals; Antidepressive Agents; Dose-Response Relationship, Drug; Drug Synergism; Gastrointestinal Transit; Lethal Dose 50; Male; Mice; Mice, Inbred Strains; Morphine; Narcotics; Piperazines; Receptors, Opioid; Triazoles | 1992 |
Novel serotonergic mechanisms and clinical experience with nefazodone.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Piperazines; Serotonin; Triazoles | 1992 |
Nefazodone--a novel antidepressant--may increase REM sleep.
Topics: Adult; Antidepressive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Humans; Male; Monitoring, Physiologic; Piperazines; Reaction Time; Signal Processing, Computer-Assisted; Sleep, REM; Triazoles; Wakefulness | 1992 |
Evaluation of nefazodone self-administration in rhesus monkeys.
Topics: Animals; Arousal; Cocaine; Infusions, Intravenous; Macaca mulatta; Male; Piperazines; Reinforcement, Psychology; Self Administration; Substance-Related Disorders; Triazoles | 1991 |
High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Female; Humans; Piperazines; Robotics; Spectrophotometry, Ultraviolet; Triazoles | 1991 |
Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors.
Topics: Amitriptyline; Animals; Cerebral Cortex; Dihydroalprenolol; Hippocampus; In Vitro Techniques; Male; Piperazines; Propranolol; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta; Receptors, Serotonin; Reserpine; Serotonin; Spiperone; Triazoles | 1986 |
The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.
Topics: Animals; Antidepressive Agents; Carrier Proteins; Cerebral Cortex; Dose-Response Relationship, Drug; Fluoxetine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; p-Chloroamphetamine; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptosomes; Triazoles | 1995 |
The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Decision Support Techniques; Economics, Pharmaceutical; Fluoxetine; Follow-Up Studies; Humans; Imipramine; Models, Economic; Piperazines; Treatment Outcome; Triazoles | 1995 |
Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis.
Topics: Adult; Antidepressive Agents; Dose-Response Relationship, Drug; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Nefazodone-induced mania.
Topics: Antidepressive Agents; Bipolar Disorder; Humans; Male; Middle Aged; Piperazines; Triazoles | 1995 |
An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder.
Topics: Adult; Antidepressive Agents; Arousal; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Personality Inventory; Piperazines; Psychiatric Status Rating Scales; Triazoles | 1994 |
Nefazodone for depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Humans; Piperazines; Triazoles | 1995 |
Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment.
Topics: Administration, Oral; Adult; Antidepressive Agents; Biotransformation; Body Temperature Regulation; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Humans; Male; Piperazines; Prolactin; Receptors, Serotonin; Triazoles | 1994 |
The effects of nefazodone on sleep architecture in depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Depressive Disorder; Electroencephalography; Female; Humans; Male; Middle Aged; Piperazines; Sleep; Triazoles | 1994 |
Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo.
Topics: Animals; Hypothalamus; Male; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred ICR; Piperazines; Quipazine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Trazodone; Triazoles | 1994 |
Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.
Topics: Adult; Antidepressive Agents; Drug Administration Schedule; Half-Life; Humans; Male; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Obsessive-Compulsive Disorder; Personality Development; Personality Inventory; Piperazines; Prognosis; Psychometrics; Regression Analysis; Triazoles | 1995 |
Nefazodone: a novel antidepressant.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Piperazines; Treatment Outcome; Triazoles | 1995 |
Development of obsessive symptoms during nefazodone treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Triazoles | 1996 |
Treatment of dysphoric mania with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lithium; Piperazines; Treatment Outcome; Triazoles; Valproic Acid | 1996 |
Nefazodone-induced carbamazepine toxicity.
Topics: Adult; Bipolar Disorder; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Mixed Function Oxygenases; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 1996 |
Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antidepressive Agents; Female; Humans; Kidney Diseases; Liver Cirrhosis; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.
Topics: Antidepressive Agents; Female; Humans; Kidney Diseases; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Triazoles | 1995 |
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition.
Topics: Alprazolam; Antidepressive Agents, Second-Generation; Anxiety; Cytochrome P-450 Enzyme Inhibitors; Depression; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Treatment Outcome; Triazoles | 1996 |
Antidepressant-induced mania.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder; Humans; Male; Middle Aged; Piperazines; Triazoles | 1995 |
Paresthesia as a side effect of the new antidepressant, nefazodone.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Humans; Paresthesia; Piperazines; Triazoles | 1995 |
Apparent interaction between nefazodone and cyclosporine.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Piperazines; Triazoles | 1996 |
Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextrorphan; Excitatory Amino Acid Antagonists; Humans; In Vitro Techniques; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases, O-Demethylating; Piperazines; Triazoles | 1996 |
New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder; Humans; Imipramine; Piperazines; Triazoles | 1996 |
Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Biological Availability; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Male; Piperazines; Reference Values; Triazoles | 1996 |
Visual "trails" with nefazodone treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Optical Illusions; Perceptual Disorders; Piperazines; Triazoles; Visual Perception | 1996 |
Three new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Interactions; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1996 |
Reassessment of nefazodone.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 1996 |
Nefazodone and akathisia.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Clonazepam; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Propranolol; Triazoles | 1996 |
Familial akathisia and depression treated with nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Piperazines; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Triazoles | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Nefazodone-induced spontaneous ejaculation.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Ejaculation; Humans; Male; Middle Aged; Piperazines; Sexual Dysfunctions, Psychological; Triazoles | 1996 |
Priapism: trazodone versus nefazodone.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Middle Aged; Piperazines; Priapism; Trazodone; Triazoles | 1996 |
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Biotransformation; Cyclohexanols; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Microsomes, Liver; Phenacetin; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1996 |
Probable nefazodone-induced mania in a patient with unreported bipolar disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Desipramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Patient Care Team; Piperazines; Premenstrual Syndrome; Triazoles | 1996 |
The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Humans; Male; Metabolic Clearance Rate; Phenytoin; Piperazines; Triazoles | 1997 |
Nefazodone and symptoms suggesting neurotoxicity: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Nervous System Diseases; Piperazines; Psychotic Disorders; Triazoles | 1996 |
Hair loss associated with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Hypotrichosis; Piperazines; Triazoles | 1997 |
Nefazodone-induced hypoglycemia in a diabetic patient with major depression.
Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Middle Aged; Piperazines; Triazoles | 1997 |
Serotonin syndrome associated with nefazodone and paroxetine.
Topics: Antidepressive Agents, Second-Generation; Coma; Drug Synergism; Female; Humans; Hyponatremia; Middle Aged; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Syndrome; Triazoles | 1997 |
Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder; Drug Costs; Fluoxetine; Health Care Costs; Health Policy; Health Services; Humans; Imipramine; Managed Care Programs; Patient Compliance; Piperazines; Probability; Quality-Adjusted Life Years; Treatment Failure; Treatment Outcome; Triazoles | 1997 |
Sertraline-induced anorgasmia treated with intermittent nefazodone.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Orgasm; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles | 1997 |
Nefazodone-induced mania.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder; Female; Humans; Middle Aged; Piperazines; Triazoles | 1997 |
Nefazodone- and/or sodium tetradecyl sulfate-associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder.
Topics: Antidepressive Agents, Second-Generation; Female; Fever; Humans; Leukopenia; Middle Aged; Piperazines; Premenstrual Syndrome; Sclerosing Solutions; Shivering; Sodium Tetradecyl Sulfate; Triazoles; Varicose Veins | 1997 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypotension; Panic Disorder; Piperazines; Substance Withdrawal Syndrome; Triazoles; Venlafaxine Hydrochloride | 1997 |
Nefazodone and visual side effects.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Middle Aged; Piperazines; Triazoles; Vision Disorders | 1997 |
Nefazodone. Psychomotor and cognitive effects.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cognition; Depressive Disorder; Humans; Middle Aged; Piperazines; Psychomotor Performance; Triazoles | 1997 |
Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.
Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Pindolol; Piperazines; Treatment Outcome; Triazoles | 1997 |
Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study.
Topics: Antidepressive Agents; Depressive Disorder; Female; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Regression Analysis; Temperament; Triazoles | 1997 |
Toxic effects of nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Serotonin; Triazoles; Valproic Acid | 1997 |
Toxic effects of nefazodone.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Triazoles | 1997 |
[Nefazodon (Nefadar)--a new dual serotoninergic antidepressant. Introductory press conference: "Nefazodone--new perspectives in antidepressive therapy." 25-26 April 1997].
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Piperazines; Triazoles | 1997 |
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.
Topics: Animals; Antidepressive Agents, Second-Generation; Carrier Proteins; Chromatography, High Pressure Liquid; Guinea Pigs; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Receptors, Serotonin; Serotonin Plasma Membrane Transport Proteins; Symporters; Triazoles | 1997 |
Nefazodone attenuates the behavioral and neurochemical effects of ethanol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Ethanol; Extracellular Space; Homovanillic Acid; Kinetics; Male; Microdialysis; Nucleus Accumbens; Piperazines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Triazoles | 1998 |
[Nefazodone: a new antidepressive agent. Advantages of a dual working principle].
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Sleep; Sleep Initiation and Maintenance Disorders; Triazoles | 1997 |
Parkinson's disease worsened by nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Humans; Male; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 1997 |
Interactions between cyclosporine and newer antidepressant medications.
Topics: Antidepressive Agents, Second-Generation; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Fluvoxamine; Humans; Kidney Transplantation; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 1998 |
Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Carrier Proteins; Depressive Disorder; Female; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Triazoles | 1998 |
Are two antidepressant mechanisms better than one?
Topics: Antidepressive Agents; Drug Design; Drug Synergism; Drug Therapy, Combination; Humans; Mianserin; Mirtazapine; Piperazines; Psychopharmacology; Receptors, Neurotransmitter; Triazoles | 1997 |
Nefazodone and neurotoxicity.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Carbamazepine; Cytochrome P-450 CYP2D6; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Risperidone; Triazoles | 1997 |
Nefazodone withdrawal symptoms.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Phobic Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Triazoles | 1998 |
The antidepressant, nefazodone, attenuates corticosterone-induced increases in 5-HT2A receptor-mediated behaviors in the female rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Corticosterone; Female; Male; Piperazines; Posture; Rats; Receptors, Serotonin; Sexual Behavior, Animal; Triazoles | 1998 |
Nefazodone and the treatment of panic.
Topics: Adult; Agoraphobia; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Administration Schedule; Humans; Male; Panic Disorder; Piperazines; Triazoles | 1998 |
Treatment of posttraumatic stress disorder with nefazodone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Arousal; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 1998 |
[Sleep-profile of a 72-year-old depressive female patient. Depression and sleep disorders. Significance--causes--treatment].
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Piperazines; Sleep Initiation and Maintenance Disorders; Sleep, REM; Triazoles | 1998 |
[Depression and sleep disorders. Progress in antidepressive therapy with nefazodone].
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Piperazines; Sleep Initiation and Maintenance Disorders; Triazoles | 1998 |
Treatment of depressed methadone maintenance patients with nefazodone. A case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Piperazines; Treatment Outcome; Triazoles | 1998 |
Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Paroxetine; Piperazines; Tacrolimus; Triazoles | 1998 |
Nefazodone overdose.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Drug Overdose; Female; Humans; Piperazines; Triazoles | 1998 |
Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 1998 |
REM sleep and nefazodone.
Topics: Antidepressive Agents, Second-Generation; Humans; Piperazines; Sleep, REM; Triazoles | 1998 |
Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents.
Topics: Animals; Blood-Brain Barrier; Brain; Cerebral Cortex; Head Movements; Male; Mice; p-Chloroamphetamine; Piperazines; Prodrugs; Quipazine; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Triazoles | 1998 |
Nefazodone for mood disorder associated with epilepsy.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder; Epilepsy; Humans; Male; Piperazines; Treatment Outcome; Triazoles | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Nefazodone-induced liver failure: report of three cases.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Liver; Liver Failure, Acute; Middle Aged; Piperazines; Triazoles | 1999 |
Visual field "shimmering" associated with nefazodone.
Topics: Bupropion; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Triazoles; Vision Disorders; Visual Fields | 1999 |
Modelling the cost effectiveness of antidepressant treatment in primary care.
Topics: Antidepressive Agents; Decision Support Techniques; Depressive Disorder; Female; Fluoxetine; Humans; Imipramine; Markov Chains; Models, Economic; Piperazines; Primary Health Care; Quality-Adjusted Life Years; Sensitivity and Specificity; Triazoles | 1995 |
Nefazodone withdrawal syndrome.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Piperazines; Substance Withdrawal Syndrome; Triazoles | 1999 |
Re: Nefazodone withdrawal symptoms.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Substance Withdrawal Syndrome; Triazoles | 1999 |
Treatment of chronic fatigue syndrome with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Administration Schedule; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged; Piperazines; Treatment Outcome; Triazoles | 1999 |
Adverse effect of nefazodone: hepatitis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Depression; Humans; Male; Phobic Disorders; Piperazines; Triazoles | 1999 |
Possible nefazodone withdrawal syndrome.
Topics: Adult; Dizziness; Humans; Male; Nausea; Piperazines; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Triazoles | 1999 |
The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Binding, Competitive; Female; Fluorine Radioisotopes; Humans; Male; Paroxetine; Piperazines; Pyrimidinones; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Tomography, Emission-Computed; Triazoles | 1999 |
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
Topics: Alprazolam; Antidepressive Agents; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Triazoles | 1999 |
Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Humans; Milk, Human; Piperazines; Reference Standards; Reproducibility of Results; Triazoles | 1999 |
Nefazodone-induced clitoral priapism.
Topics: Antidepressive Agents, Second-Generation; Clitoris; Depressive Disorder; Female; Humans; Middle Aged; Piperazines; Triazoles; Vaginal Diseases | 1999 |
Discontinuation symptoms with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Piperazines; Substance Withdrawal Syndrome; Triazoles | 1999 |
Serotonergic agents in the treatment of social phobia in children and adolescents: a case series.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Female; Humans; Male; Paroxetine; Phobic Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Triazoles | 1999 |
Nefazodone and visual disturbances.
Topics: Antidepressive Agents, Second-Generation; Drug Monitoring; Humans; Male; Middle Aged; Patient Education as Topic; Piperazines; Triazoles; Vision Disorders | 1999 |
Nefazadone-induced acute dystonic reaction.
Topics: Antidepressive Agents, Second-Generation; Antiemetics; Benztropine; Diphenhydramine; Drug Interactions; Dystonia; Female; Humans; Meclizine; Middle Aged; Parasympatholytics; Piperazines; Time Factors; Triazoles | 1999 |
Nefazodone and cyclosporine drug-drug interaction.
Topics: Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Oxidoreductases, N-Demethylating; Piperazines; Triazoles | 1999 |
Nefazodone attenuates the stress-induced facilitation of wet dog shaking behaviour but not the facilitation of sexual behaviour in female rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Corticosterone; Estradiol; Female; Male; Piperazines; Posture; Progesterone; Rats; Rats, Long-Evans; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Reflex; Sexual Behavior, Animal; Stress, Psychological; Triazoles | 1999 |
Combining nefazodone and midazolam during ECT.
Topics: Antidepressive Agents, Second-Generation; Combined Modality Therapy; Drug Interactions; Dysthymic Disorder; Electroconvulsive Therapy; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Neuromuscular Depolarizing Agents; Piperazines; Succinylcholine; Thiopental; Treatment Outcome; Triazoles | 1999 |
Akinetopsia from nefazodone toxicity.
Topics: Antidepressive Agents, Second-Generation; Female; Humans; Male; Middle Aged; Motion Perception; Perceptual Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Triazoles | 1999 |
Nefazodone-induced visual disturbances.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Humans; Male; Piperazines; Triazoles; Vision Disorders | 1999 |
Safety of sildenafil for antidepressant-related sexual dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Half-Life; Humans; Mixed Function Oxygenases; Phosphodiesterase Inhibitors; Piperazines; Purines; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sulfones; Triazoles | 1999 |
Acute liver failure after treatment with nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Female; Humans; Liver Failure, Acute; Piperazines; Triazoles | 1999 |
Carbamazepine-nefazodone interaction in healthy subjects.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Area Under Curve; Carbamazepine; Cytochrome P-450 CYP2D6; Drug Interactions; Humans; Male; Piperazines; Triazoles | 2000 |
Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2000 |
A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Triazoles | 2000 |
Nafazodone-induced palinopsia.
Topics: Afterimage; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Humans; Male; Middle Aged; Piperazines; Triazoles | 2000 |
Comment: possible interaction between nefazodone and pravastatin.
Topics: Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Creatine Kinase; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Mixed Function Oxygenases; Piperazines; Pravastatin; Triazoles | 2000 |
Sertraline-induced anorgasmia reversed by nefazodone.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Ejaculation; Humans; Libido; Male; Middle Aged; Piperazines; Sertraline; Triazoles | 1999 |
Reversible nefazodone-induced liver failure.
Topics: Antidepressive Agents, Second-Generation; Biopsy; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Failure; Middle Aged; Piperazines; Triazoles | 2000 |
Treatment of chronic depression.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Humans; Piperazines; Triazoles | 2000 |
Nefazodone-associated subjective complaints of burning sensations.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Paresthesia; Piperazines; Triazoles | 2000 |
Antidepressants and the serotonin syndrome in general practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Family Practice; Female; Humans; Male; Medical Records; Middle Aged; Piperazines; Serotonin Syndrome; Triazoles | 1999 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
Serotonin syndrome from addition of low-dose trazodone to nefazodone.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Trazodone; Triazoles | 2000 |
Effects of nefazodone on the immune system of mice.
Topics: Animals; Antidepressive Agents; Concanavalin A; Female; Immunity; Mice; Mice, Inbred BALB C; Norepinephrine; Phagocytosis; Piperazines; Serotonin; Serotonin Antagonists; Spleen; Stress, Physiological; T-Lymphocytes; Thymus Gland; Triazoles | 2000 |
Nefazodone-induced acute liver failure.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Humans; Liver Failure; Male; Middle Aged; Piperazines; Triazoles | 2000 |
Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.
Topics: Alkylation; Antidepressive Agents, Second-Generation; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Histamine H1 Antagonists; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Sertraline; Terfenadine; Triazoles | 1998 |
Acupuncture and neuropathy.
Topics: Acupuncture Therapy; Antidepressive Agents, Second-Generation; Blood Platelets; Combined Modality Therapy; Diabetic Neuropathies; Humans; Male; Middle Aged; Neuralgia; Piperazines; Serotonin; Treatment Outcome; Triazoles | 2000 |
Nefazodone for PTSD.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Arousal; Humans; Piperazines; Stress Disorders, Post-Traumatic; Triazoles | 2000 |
Nefazodone and hypotension: complication or coincidence.
Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Depressive Disorder, Major; Female; Humans; Hypotension; Male; Middle Aged; Piperazines; Retrospective Studies; Triazoles | 1997 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Piperazines; Poison Control Centers; Prospective Studies; Sex Distribution; Suicide, Attempted; Treatment Outcome; Triazoles; United States | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; Piperazines; Placebos; Psychotherapy; Research Design; Triazoles | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; Piperazines; Psychotherapy; Research Design; Triazoles | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Disorder; Humans; Outcome Assessment, Health Care; Piperazines; Placebos; Psychotherapy; Triazoles | 2000 |
Nefazodone, psychotherapy, and their combination for chronic depression.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Disorder; Humans; Piperazines; Psychotherapy; Severity of Illness Index; Triazoles | 2000 |
[Acute liver failure ascribed to nefazodone: importance of 'postmarketing surveillance' for recently introduced drugs].
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Humans; Liver Failure, Acute; Male; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Triazoles; World Health Organization | 2000 |
LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone.
Topics: Animals; Antidepressive Agents, Second-Generation; Carrier Proteins; Cerebral Cortex; Cyclic S-Oxides; Guinea Pigs; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine; Piperazines; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Synaptosomes; Thiadiazoles; Triazoles | 2000 |
[Familial myoclonus-dystonia syndrome associated with panic attacks].
Topics: Adult; Chromosome Aberrations; Chromosome Disorders; Dystonic Disorders; Female; Genes, Dominant; Humans; Myoclonus; Panic Disorder; Pedigree; Piperazines; Syndrome; Triazoles | 2000 |
Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Breast Feeding; Depression, Postpartum; Feeding Behavior; Female; Humans; Infant, Newborn; Infant, Premature; Milk, Human; Piperazines; Sleep Stages; Triazoles | 2000 |
Nefazodone in the breast milk of nursing mothers: a report of two patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression, Postpartum; Female; Humans; Milk, Human; Piperazines; Triazoles | 2000 |
Psychotherapy vindicated?
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Humans; Piperazines; Triazoles | 2000 |
Neurtropenia due to nefazodone, interaction or coincidence?
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Female; Humans; Neutropenia; Piperazines; Triazoles | 2000 |
Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Pressure; Case-Control Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Down-Regulation; Female; Heart Rate; Humans; Male; Middle Aged; Piperazines; Serotonin; Sympathetic Nervous System; Triazoles | 2001 |
Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry.
Topics: Animals; Antifungal Agents; Atmospheric Pressure; Chromatography, High Pressure Liquid; Itraconazole; Mass Spectrometry; Piperazines; Quality Control; Rats; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2001 |
Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Luteal Phase; Piperazines; Premenstrual Syndrome; Psychiatric Status Rating Scales; Triazoles | 2001 |
Increased throughput in quantitative bioanalysis using parallel-column liquid chromatography with mass spectrometric detection.
Topics: Chromatography, Liquid; Piperazines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Time Factors; Triazoles | 2001 |
Increase in plasma levels of clozapine and norclozapine after administration of nefazodone.
Topics: Adult; Clozapine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Male; Mixed Function Oxygenases; Piperazines; Schizophrenia, Paranoid; Triazoles | 2001 |
[The antidepressant nefazodone. Healthy sleep fosters compliance].
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Patient Compliance; Piperazines; Sleep Stages; Treatment Outcome; Triazoles | 2001 |
P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Topics: Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Drug Interactions; Humans; Piperazines; Trazodone; Triazoles; Verapamil | 2001 |
Remission of SSRI-induced akathisia after switch to nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 2001 |
Nefazodone may inhibit the metabolism of carbamazepine: three case reports.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Depressive Disorder; Female; Humans; Middle Aged; Piperazines; Triazoles | 2001 |
LC determination and purity evaluation of nefazodone HCl in bulk drug and pharmaceutical formulations.
Topics: Antidepressive Agents, Second-Generation; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Piperazines; Tablets; Triazoles | 2001 |
Bupropion and drug-induced parkinsonism.
Topics: Bupropion; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Piperazines; Triazoles | 2001 |
Long-term treatment of recurrent and chronic depression.
Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost of Illness; Depressive Disorder; Disability Evaluation; Drug Administration Schedule; Fluoxetine; Humans; Piperazines; Placebos; Recurrence; Treatment Outcome; Triazoles | 2001 |
Possible interaction of zopiclone and nefazodone.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Piperazines; Triazoles | 2001 |
QTc prolongation and drugs.
Topics: Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Histamine H1 Antagonists; Humans; Long QT Syndrome; Loratadine; Oxidoreductases, N-Demethylating; Piperazines; Triazoles | 2001 |
A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Contraceptives, Oral, Combined; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Mixed Function Oxygenases; Piperazines; Triazoles | 2001 |
Nefazodone may increase anxiety in panic disorder.
Topics: Adult; Anxiety; Humans; Male; Panic Disorder; Piperazines; Triazoles | 2002 |
Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Female; Humans; Piperazines; Premenstrual Syndrome; Severity of Illness Index; Treatment Outcome; Triazoles | 2002 |
Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes.
Topics: Animals; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Humans; Insecta; Ketoconazole; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Transfection; Triazoles; Tumor Cells, Cultured | 2002 |
Hepatotoxicity associated with the new antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Drug Monitoring; Female; Humans; Incidence; Liver Diseases; Piperazines; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Triazoles | 2002 |
From the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration | 2002 |
Antidepressant dosing and switching guidelines: focus on nefazodone.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Humans; Piperazines; Practice Guidelines as Topic; Secondary Prevention; Triazoles | 2002 |
Serzone. Beware of dangerous liver problems.
Topics: Antidepressive Agents, Second-Generation; Contraindications; Drug Labeling; Humans; Liver Failure; Piperazines; Triazoles | 2002 |
Loratadine/nefazodone interaction.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; Piperazines; Triazoles | 2002 |
Hepatic adverse reactions associated with nefazodone.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antidepressive Agents, Second-Generation; Canada; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Function Tests; Male; Middle Aged; Piperazines; Triazoles | 2002 |
Effects of nefazodone on voluntary ethanol consumption induced by isolation stress in young and aged rats.
Topics: Aging; Alcohol Drinking; Animals; Antidepressive Agents, Second-Generation; Anxiety; Corticosterone; Female; Hippocampus; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin Antagonists; Social Isolation; Stress, Psychological; Triazoles | 2002 |
Nefazodone treatment of dysthymic disorder an open, long-term, prospective pilot study.
Topics: Adult; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Triazoles | 2002 |
Rhabdomyolysis with simvastatin and nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Piperazines; Rhabdomyolysis; Simvastatin; Triazoles | 2002 |
[Acute liver failure in nefazodone therapy? A case report].
Topics: Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Fatal Outcome; Humans; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Piperazines; Recurrence; Triazoles | 2002 |
Nefazodone and liver damage.
Topics: Antidepressive Agents, Second-Generation; Humans; Liver; Liver Failure; Piperazines; Triazoles; United States | 2002 |
Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1.
Topics: Alanine Transaminase; Antidepressive Agents, Second-Generation; Aspartate Aminotransferases; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Hepatitis C; Humans; Liver Transplantation; Male; Mixed Function Oxygenases; Piperazines; Substance-Related Disorders; Tacrolimus; Triazoles | 2002 |
Reversible penile priapism associated with nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Humans; Male; Piperazines; Priapism; Triazoles | 2002 |
Nefazodone alters NPY immunostaining in rat arcuate-paraventricular projection without changes in food intake and body weight.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Antidepressive Agents, Second-Generation; Arcuate Nucleus of Hypothalamus; Body Weight; Energy Intake; Immunohistochemistry; Male; Neuropeptide Y; Paraventricular Hypothalamic Nucleus; Piperazines; Rats; Rats, Sprague-Dawley; Triazoles | 2002 |
Pharmacokinetically induced benzodiazepine withdrawal.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Interactions; Female; Humans; Middle Aged; Panic Disorder; Piperazines; Substance Withdrawal Syndrome; Triazoles; Venlafaxine Hydrochloride | 2001 |
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Binding Sites; Brain; Depression; Female; Humans; Male; Pilot Projects; Piperazines; Receptors, Dopamine; Receptors, Serotonin; Severity of Illness Index; Surveys and Questionnaires; Thalamus; Tomography, Emission-Computed; Triazoles | 2002 |
Enhanced resolution triple-quadrupole mass spectrometry for fast quantitative bioanalysis using liquid chromatography/tandem mass spectrometry: investigations of parameters that affect ruggedness.
Topics: Chromatography, Liquid; Mass Spectrometry; Molecular Structure; Pharmaceutical Preparations; Piperazines; Quality Control; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Temperature; Triazoles | 2003 |
Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum.
Topics: Algorithms; Antiparkinson Agents; Calibration; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Oxidation-Reduction; Piperazines; Piribedil; Solvents; Tablets; Trazodone; Triazoles | 2003 |
Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as Topic; Combat Disorders; Depressive Disorder, Major; Follow-Up Studies; Humans; Male; Middle Aged; Middle East; Patient Compliance; Piperazines; Sleep; Treatment Outcome; Triazoles; Veterans | 2002 |
Withdrawing drugs: nefazodone, the start of the latest saga.
Topics: Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Drug Approval; Drug Monitoring; Humans; Piperazines; Product Surveillance, Postmarketing; Triazoles | 2003 |
Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Bayes Theorem; Chemical and Drug Induced Liver Injury; Cyclohexanols; Databases, Factual; Humans; Neural Networks, Computer; Pancreatitis; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride; World Health Organization | 2003 |
Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antidotes; Biotransformation; Blood Pressure; Charcoal; Depressive Disorder; Drug Overdose; Electrocardiography; Female; Fluid Therapy; Half-Life; Humans; Long QT Syndrome; Piperazines; Triazoles | 2003 |
Central and peripheral vision loss associated with nefazodone usage.
Topics: Adult; Antidepressive Agents, Second-Generation; Color Perception; Electroretinography; Evoked Potentials, Visual; Female; Humans; Piperazines; Retina; Retinal Diseases; Triazoles; Vision Disorders; Visual Acuity; Visual Fields | 2003 |
Conditioned taste aversion: modulation by 5-HT receptor activity and corticosterone.
Topics: Administration, Oral; Animals; Avoidance Learning; Conditioning, Classical; Corticosterone; Extinction, Psychological; Hypothalamo-Hypophyseal System; Injections; Lithium Chloride; Male; Piperazines; Pituitary-Adrenal System; Rats; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Solutions; Sucrose; Taste; Time Factors; Triazoles | 2003 |
Early onset, nefazodone-induced fulminant hepatic failure.
Topics: Antidepressive Agents, Second-Generation; Female; Humans; Liver Failure; Male; Middle Aged; Piperazines; Time Factors; Triazoles | 2003 |
Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control.
Topics: Animals; Antidepressive Agents, Second-Generation; Conditioning, Operant; Discrimination, Psychological; DOM 2,5-Dimethoxy-4-Methylamphetamine; Dose-Response Relationship, Drug; Drug Synergism; Hallucinogens; Male; Piperazines; Rats; Rats, Inbred F344; Stimulation, Chemical; Triazoles | 2003 |
Rhabdomyolysis associated with simvastatin-nefazodone therapy.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Piperazines; Rhabdomyolysis; Simvastatin; Triazoles | 2003 |
Nefazodone (Serzone) withdrawn because of hepatotoxicity.
Topics: Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Humans; Jaundice; Liver; Necrosis; Piperazines; Triazoles | 2003 |
A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Drug Design; Energy Metabolism; Haplorhini; Mass Spectrometry; Metabolic Clearance Rate; Microsomes, Liver; Pharmaceutical Preparations; Piperazines; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2003 |
The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain Chemistry; Depressive Disorder; Desipramine; Dopamine; Extracellular Space; Microdialysis; Nucleus Accumbens; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin; Swimming; Triazoles | 2004 |
Dyskinetopsia during light adaptation associated with nefazodone treatment.
Topics: Adaptation, Ocular; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Motion Perception; Piperazines; Triazoles; Vision Disorders | 2003 |
Nefazodone-associated torsade de pointes.
Topics: Antidepressive Agents, Second-Generation; Female; Humans; Middle Aged; Piperazines; Torsades de Pointes; Triazoles | 2004 |
Discontinuation symptoms associated with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Piperazines; Substance Withdrawal Syndrome; Triazoles | 2003 |
A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Personality Assessment; Personality Inventory; Piperazines; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Treatment Outcome; Triazoles | 2004 |
Seroquel, Serzone and seizures.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dibenzothiazepines; Drug Packaging; Female; Humans; Medication Errors; Piperazines; Quetiapine Fumarate; Seizures; Triazoles | 2004 |
Comparative toxicity of citalopram and the newer antidepressants after overdose.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Drug Overdose; Female; Humans; Male; Mianserin; Mirtazapine; Piperazines; Poisoning; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 2004 |
Nefazodone-induced liver failure.
Topics: Depressive Disorder; Humans; Liver Failure, Acute; Male; Middle Aged; Piperazines; Triazoles | 2004 |
Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Brain Chemistry; Cell Count; Cerebral Cortex; Emotions; Immunohistochemistry; Male; Pain; Periaqueductal Gray; Piperazines; Raphe Nuclei; Rats; Rats, Wistar; Reaction Time; Receptors, Opioid, mu; Sensation; Somatosensory Cortex; Swimming; Triazoles | 2004 |
Effects of nefazodone on the development of experimentally induced tumors in stressed rodents.
Topics: Animals; Antidepressive Agents, Second-Generation; Carcinoma 256, Walker; Male; Mammary Tumor Virus, Mouse; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Piperazines; Rats; Rats, Sprague-Dawley; Retroviridae Infections; Stress, Psychological; Triazoles; Tumor Cells, Cultured; Tumor Virus Infections | 2004 |
[Withdrawal of a drug from the market for safety reasons: process and communication].
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Attitude of Health Personnel; Chemical and Drug Induced Liver Injury; Communication; Drug Industry; Drug Information Services; Drug-Related Side Effects and Adverse Reactions; Humans; Interprofessional Relations; Piperazines; Switzerland; Triazoles | 2004 |
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.
Topics: Adrenergic beta-Antagonists; Adult; Alleles; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzimidazoles; Cohort Studies; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Pindolol; Piperazines; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Triazoles | 2004 |
Newer antidepressants in pregnancy: prospective outcome of a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Mianserin; Mirtazapine; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Teratogens; Triazoles; Turkey; Venlafaxine Hydrochloride | 2004 |
Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.
Topics: Antidepressive Agents, Second-Generation; Benzoquinones; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Imines; Microsomes, Liver; Piperazines; Triazoles | 2005 |
Incomplete patient drug information still a problem.
Topics: Analgesics; Canada; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Information Services; Patient Education as Topic; Piperazines; Product Labeling; Safety; Triazoles | 2004 |
[Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring].
Topics: Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Statistics as Topic; Triazoles | 2004 |
Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Models, Animal; Dopamine; Extracellular Space; Male; Microdialysis; Models, Animal; Nucleus Accumbens; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Spiro Compounds; Staining and Labeling; Sulfonamides; Time Factors; Triazoles | 2005 |
Nefazodone for the treatment of postpartum depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Controlled Clinical Trials as Topic; Depression, Postpartum; Female; Humans; Infant, Newborn; Maternal Welfare; Piperazines; Pregnancy; Time Factors; Treatment Outcome; Triazoles | 2005 |
Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Community Mental Health Centers; Drug Prescriptions; Drug Utilization; Female; Germany; Hospitals, Psychiatric; Humans; Mental Disorders; Mianserin; Middle Aged; Mirtazapine; Morpholines; Piperazines; Practice Patterns, Physicians'; Reboxetine; Rural Health Services; Selective Serotonin Reuptake Inhibitors; Sex Factors; Switzerland; Triazoles; Urban Health Services | 2005 |
Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone.
Topics: Animals; Antidepressive Agents, Second-Generation; Bile Acids and Salts; Bile Canaliculi; Biological Transport; Buspirone; Cells, Cultured; Hepatocytes; Humans; Microsomes, Liver; Piperazines; Rats; Rats, Sprague-Dawley; Trazodone; Triazoles | 2006 |
Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements.
Topics: Antidepressive Agents; Cells, Cultured; Humans; Microsomes, Liver; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Triazoles | 2006 |
Medical management of depression.
Topics: Chemical and Drug Induced Liver Injury; Depressive Disorder; Duloxetine Hydrochloride; Humans; Liver Function Tests; Piperazines; Selective Serotonin Reuptake Inhibitors; Thiophenes; Triazoles | 2006 |
Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Topics: Amines; Animals; Chromatography, Liquid; Glutathione; Humans; Imines; Mass Spectrometry; Microsomes, Liver; Nicotine; Piperazines; Potassium Cyanide; Prochlorperazine; Rats; Triazoles | 2005 |
Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data.
Topics: Biotransformation; Chromatography, Liquid; Humans; Mass Spectrometry; Models, Chemical; Molecular Structure; Omeprazole; Piperazines; Spectrometry, Mass, Electrospray Ionization; Technology, Pharmaceutical; Triazoles | 2006 |
Cardiac conduction disturbances after an overdose of nefazodone and gabapentin.
Topics: Adult; Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids; Drug Overdose; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Piperazines; Tachycardia, Sinus; Triazoles | 2006 |
Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.
Topics: 5-Hydroxytryptophan; Analgesics, Opioid; Animals; Clozapine; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Fluvoxamine; Indophenol; Levorphanol; Male; Methadone; Mice; Morphine; Naloxone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Piperazines; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Stereotyped Behavior; Tics; Tourette Syndrome; Tramadol; Triazoles | 2007 |
High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS.
Topics: Antidepressive Agents, Second-Generation; Chromatography, Liquid; Humans; Molecular Structure; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors; Triazoles | 2007 |
'N-in-one' strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan.
Topics: Analgesics; Biotransformation; Chromatography, High Pressure Liquid; Humans; Microsomes, Liver; Piperazines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2007 |
Serzone semantics.
Topics: Antidepressive Agents, Second-Generation; Drugs, Generic; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Terminology as Topic; Triazoles | 2007 |
High-field asymmetric waveform ion mobility spectrometry coupled with liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-FAIMS-MS/MS) multi-component bioanalytical method development, performance evaluation and demonstration of
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Feasibility Studies; Flow Injection Analysis; Ions; Piperazines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2007 |
Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms.
Topics: Antidepressive Agents, Second-Generation; Biotransformation; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Microsomes, Liver; Piperazines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2007 |
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Mirtazapine; Models, Biological; Piperazines; Reaction Time; Research Design; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sexual Dysfunction, Physiological; Treatment Outcome; Triazoles | 2008 |
Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Cyanides; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Glutathione; Humans; Microsomes, Liver; Piperazines; Quinolones; Triazoles | 2008 |
In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone.
Topics: Adenosine Triphosphate; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Cell Line; Cell Respiration; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Hepatocytes; Humans; Male; Membrane Potential, Mitochondrial; Metabolic Networks and Pathways; Mitochondria, Liver; Oxidative Phosphorylation; Oxygen Consumption; Piperazines; Rats; Rats, Sprague-Dawley; Trazodone; Triazoles | 2008 |
How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Asthma; Bronchodilator Agents; Buspirone; Clozapine; Comorbidity; Cooperative Behavior; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Humans; Long-Term Care; Patient Care Team; Piperazines; Referral and Consultation; Schizophrenia; Schizophrenic Psychology; Theophylline; Triazoles | 2008 |
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Remission Induction; ROC Curve; Severity of Illness Index; Time Factors; Triazoles | 2008 |
Long-term exposure of mouse pancreatic islets to oleate or palmitate results in reduced glucose-induced somatostatin and oversecretion of glucagon.
Topics: Animals; Cells, Cultured; Glucagon; Glucose; Islets of Langerhans; Mice; Oleic Acid; Palmitic Acid; Piperazines; Somatostatin; Triazoles | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Topics: Acetaminophen; Binding Sites; Buspirone; Carbamazepine; Diclofenac; Diphenhydramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hepatocytes; Humans; Indomethacin; Meloxicam; Microsomes, Liver; Molecular Structure; Paroxetine; Piperazines; Propranolol; Raloxifene Hydrochloride; Simvastatin; Structure-Activity Relationship; Thiazines; Thiazoles; Ticrynafen; Toxicity Tests; Triazoles | 2008 |
Utility of multivariate analysis in support of in vitro metabolite identification studies: retrospective analysis using the antidepressant drug nefazodone.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Stability; Humans; In Vitro Techniques; Microsomes, Liver; Multivariate Analysis; Piperazines; Tandem Mass Spectrometry; Triazoles | 2010 |
Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone.
Topics: Adrenal Insufficiency; Adult; Analgesics; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Piperazines; Triamcinolone Acetonide; Triazoles | 2010 |
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clomipramine; Cyclohexanols; Depressive Disorder; Female; Genetic Association Studies; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1B; Severity of Illness Index; Suicidal Ideation; Tacrolimus Binding Proteins; Triazoles; Venlafaxine Hydrochloride; Young Adult | 2011 |
Visual trails: do the doors of perception open periodically?
Topics: Anticonvulsants; Antidepressive Agents; Female; Fructose; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mianserin; Middle Aged; Mirtazapine; Perceptual Disorders; Piperazines; Topiramate; Trazodone; Triazoles; Visual Perception | 2011 |
Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.
Topics: Apoptosis; Benzophenones; Calcium; Caspase 3; Chemical and Drug Induced Liver Injury; Chromans; Hep G2 Cells; Humans; Image Processing, Computer-Assisted; Imidazoles; Liver; Microscopy, Fluorescence; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nitrophenols; Piperazines; Thiazolidinediones; Tolcapone; Triazoles; Troglitazone | 2012 |
Role of electrostatic potential in the in silico prediction of molecular bioactivation and mutagenesis.
Topics: Acetaminophen; Aniline Compounds; Chemistry, Pharmaceutical; Computer Simulation; Cytosine; DNA; Drug Design; Hot Temperature; Imidazoles; Models, Molecular; Mutagenesis; Neonicotinoids; Nitro Compounds; Piperazines; Solubility; Static Electricity; Triazoles; Vinyl Chloride; Water | 2013 |
Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Biological Transport; Chemical and Drug Induced Liver Injury; Flow Cytometry; Fluoroquinolones; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Humans; Inflammation; Ketolides; Lipopolysaccharides; Liver; Naphthyridines; Piperazines; Sulfonamides; Triazoles; Tumor Necrosis Factor-alpha; Xenobiotics | 2013 |
A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method.
Topics: Binding Sites; Cardiotoxins; Computer Simulation; Electrophysiological Phenomena; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Patch-Clamp Techniques; Piperazines; Protein Conformation; Stereoisomerism; Triazoles | 2014 |
Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma.
Topics: Animals; Atropine; Captopril; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Flutamide; Lamivudine; Liver; Male; Mannitol; Metabolomics; Methotrexate; Neomycin; Oxidative Stress; Phenytoin; Piperazines; Propylthiouracil; Rats; Rats, Wistar; Streptomycin; Triazoles; Valproic Acid; Vancomycin; Zidovudine | 2014 |
Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
Topics: Animals; Antidepressive Agents, Second-Generation; Bile; Child, Preschool; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Liver; Male; Mice, Inbred ICR; Mice, Knockout; Mice, SCID; Microsomes, Liver; Piperazines; Triazoles | 2016 |
Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Topics: Animals; Antidepressive Agents, Second-Generation; Cardiotoxicity; Cardiotoxins; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Ion Channels; Myocytes, Cardiac; Piperazines; Protein Transport; Rats; Rats, Sprague-Dawley; Triazoles | 2016 |
Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity.
Topics: Antidepressive Agents, Second-Generation; Gene Expression; Hep G2 Cells; Humans; Liver; Membrane Potential, Mitochondrial; Mitochondria, Liver; Piperazines; Triazoles | 2016 |
Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells.
Topics: Activating Transcription Factor 4; Antidepressive Agents, Second-Generation; Cell Death; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Enzyme Activation; Eukaryotic Initiation Factor-2; Hep G2 Cells; Hepatocytes; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperazines; RNA Interference; RNA Splicing; Signal Transduction; Time Factors; Transcription Factor CHOP; Transfection; Triazoles; X-Box Binding Protein 1 | 2016 |
Effect of human pharmaceuticals common to aquatic environments on hepatic CYP1A and CYP3A-like activities in rainbow trout (Oncorhynchus mykiss): An in vitro study.
Topics: Animals; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; Humans; Liver; Microsomes, Liver; Oncorhynchus mykiss; Pharmaceutical Preparations; Piperazines; Triazoles; Water Pollutants, Chemical | 2018 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles | 2018 |
Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytosol; Drug Interactions; Humans; Ketolides; Kinetics; Microsomes, Liver; Pharmaceutical Preparations; Piperazines; Triazoles | 2019 |
Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the
Topics: Amiodarone; Benzbromarone; Chemical and Drug Induced Liver Injury; Galactose; Glucose; Hep G2 Cells; Humans; Metabolomics; Mitochondria, Liver; Piperazines; Triazoles; Troglitazone; Tumor Cells, Cultured | 2019 |
Untargeted Metabolomics Reveals Anaerobic Glycolysis as a Novel Target of the Hepatotoxic Antidepressant Nefazodone.
Topics: Adenosine Triphosphate; Anaerobiosis; Animals; Antidepressive Agents; Biological Transport; Cell Line; Glucose; Glycolysis; Humans; Liver; Metabolomics; Mice; Piperazines; Triazoles | 2020 |
Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach.
Topics: Administration, Oral; Aprepitant; Computer Simulation; Drug Liberation; Food-Drug Interactions; Furosemide; Hepatobiliary Elimination; Humans; Intestinal Absorption; Intestinal Elimination; Intestinal Mucosa; Models, Biological; Permeability; Piperazines; Solubility; Triazoles | 2021 |
TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy.
Topics: Antimalarials; Autophagy; Cell Survival; Chloroquine; Fluoroquinolones; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Humans; Levofloxacin; MAP Kinase Kinase 4; Naphthyridines; Piperazines; Ribosomal Protein S6 Kinases, 70-kDa; Serotonin and Noradrenaline Reuptake Inhibitors; TOR Serine-Threonine Kinases; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results w
Topics: Acetaminophen; Activation, Metabolic; Amiodarone; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Cytochrome P-450 Enzyme System; Glutathione; HEK293 Cells; Hepatocytes; Humans; Ketoconazole; Piperazines; Triazoles; Troglitazone | 2022 |